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Many breast cancers have spawned clinically undetectable metastatic colonies 
even prior to diagnosis. The eventual outgrowth of these microscopic lesions causes 
metastatic relapse and death of an estimated 40,000 women in the US. However, how 
disseminated cancer cells convert to overt metastases remains largely unknown. 
Immunosuppression within the primary tumor microenvironment enables tumor 
progression; however, how tumors maintain immune suppression once outside the 
immune-protective environment of the primary tumor is unclear.  
Macrophage Stimulating Protein (MSP) is activated via cleavage by a protease, 
matriptase, and binds to its receptor, Ron, which is found on epithelial cells, osteoclasts, 
and macrophages. Co-overexpression of MSP/Matriptase/Ron is a strong independent 
prognostic factor for both metastasis and death in breast cancer patients. Additionally, 
overexpression of MSP in mouse mammary tumor cells resulted in increased tumor 
growth rate and significantly increased spontaneous metastasis to the lungs, lymphatics 
and bones.  
We utilized a model of breast cancer metastasis, along with tissue 
complementation strategies, to interrogate the role of MSP/Ron in metastasis. Tumor 
growth was similar between WT and Ron knockout hosts. However, loss of host Ron 
abrogated pulmonary metastasis, specifically by preventing the outgrowth of seeded 
metastatic colonies. 
 iv  
We discovered that tumor-bearing Ron knockout hosts had a significant increase in 
CD8+ T cell levels in their spleen and increased levels of infiltrating CD8+ T cells in the 
tumor stroma. CD8+ T cells from Ron knockout hosts had increased cytolytic ability in 
vitro and in vivo, while ablation of CD8+ T cells in Ron TK-/- hosts restored levels of 
metastasis. Therapeutically, BMS-777607, a Ron inhibitor, decreased lung colonization in 
both a prophalytic and adjuvant setting. This was dependent on CD8+ T cells, as depletion 
of CD8+ T cells in the context of drug treatment did not decrease colonization. 
In summary, my dissertation shows that MSP/Ron pathway is a key mediator of 
conversion of micrometastases to metastatic lesions in lungs, by suppressing antitumor 
CD8+ T cell immunity. Clinically, our findings suggest that Ron inhibitors may be 
immunotherapeutic drugs. This may impact clinical development of Ron inhibitors, 
including clinical trial design, monitoring of clinical efficacy, patient selection, and 
combination therapies. 
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INTRODUCTION TO BREAST CANCER AND 
THE PROBLEM OF METASTASIS 
  
2 
Introduction to mammary biology 
The mammary gland is a milk-producing exocrine organ, comprised of the stroma 
(adipocytes, fibroblasts, blood vessels, inflammatory cells, extracellular matrix) and 
epithelium (branching ductal-lobular system) (1). Mammary gland development occurs in 
defined stages, consisting of embryonic, prepubertal, pregnancy, lactation and involution. 
During embryonic development, crosstalk between the epithelium and mesenchyme 
specifies the mammary bud (2). After birth, mammary development is arrested until 
puberty. Subsequently, during puberty, elongation of the ducts and secondary branching 
occurs. The final developmental fate of the mammary gland occurs with pregnancy and 
lactation. During this period, reproductive hormones cause the differentiation of the 
mammary epithelium into secretory, milk-producing lobular alveoli (3). As pregnancy 
progresses, milk proteins are expressed, and there is formation of lipid droplets. Finally, 
following lactation, there is extensive remodeling, wherein the alveolar cells and most of 
the mammary epithelia are removed by apoptosis, a process called involution (4).  
Breast cancer is reminiscent of many aspects of mammary gland development (5). 
For example, during development, epithelial cells invade the stroma, undergoing repeated 
branching to create the ducts that deliver milk. Additionally, pregnancy results in massive 
tissue remodeling, accompanied by massive epithelial cell proliferation. A large number 
of genes influence ductal and alveolar morphogenesis, including estrogen receptor (ER), 
progesterone receptor (PR), and transforming growth factor-! (TGF!), all genes that are 
involved in tumorgenesis (3,6). Each estrous cycle causes a burst of proliferation, and the 
number of menstrual cycles correlates with breast cancer risk. However, full term 
pregnancy can be protective in young women (7), perhaps due to the contribution of 
involution in removing many potentially transformed cells (4). Another proposed 
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mechanism is that terminal differentiation of mammary stem cells after pregnancy 
decreases the number of cells that can undergo future oncogenic mutations (8).  
 
Breast cancer epidemiology, diagnosis and treatment 
Breast cancer is the most common cancer among women, with approximately 1.4 
million women diagnosed per year and an estimated 460,000 dying annually due to the 
disease (9). The incidence of breast cancer worldwide is increasing due to a number of 
factors, including the introduction of mammography, which allows better detection, as 
well as changes in reproductive patterns like delayed childbearing and decreased number 
of children (10). 
Breast cancer is diagnosed in a variety of ways. Classic mammographic findings of 
breast cancer include the presence of a soft tissue masses with spikes and clustered 
microcalcifications, or calcium particles of various size and shapes (11). A significant 
limitation of mammography is the obscuring of the tumor due to the dense overlying 
tissue, which limits the sensitivity of detection (12). In this setting, magnetic resonance 
imaging (MRI) may complement mammographic screening. MRI is also typically used to 
screen women at the highest risk for breast cancer to avoid cumulative radiation from 
frequent mammographies (13). Although the increased use of screening mammography 
has substantially increased the detection and incidence of breast cancer (14), the effect of 
early screening on breast cancer mortality is less significant. Recent studies have shown 
that early screening is responsible for a small percentage of the reduction of breast cancer 
mortality, suggesting that the decreasing mortality trends may be largely due to improved 
treatment rather than early detection (15). 
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Following diagnosis based on biopsy, the patient undergoes testing to ascertain 
the subtype, staging and extent of the cancer to guide therapeutic decisions. Newly 
diagnosed breast cancers are tested for estrogen receptor (ER) and progesterone receptor 
(PR) expression and for overexpression of human epidermal growth factor 2 (HER2) (16). 
These clinical markers have both prognostic value and therapeutic value (17). Women 
with ER/PR+ breast cancer who receive no systemic therapy have a 10% decreased 
chance of recurrence at five years than patients whose tumors are ER/PR negative (18). 
Patients whose tumors are ER/PR+, however, are candidates for endocrine therapy as 
neoadjuvant or adjuvant treatment. Endocrine therapy results in a drop in the risk of 
recurrence of 47% for ER/PR+ patients (19). Neoadjuvant therapy refers to the systemic 
treatment of breast cancer before surgery, while adjuvant therapy refers to treatment 
postsurgery. Patients whose tumors are HER2 positive are also candidates for HER2-
directed therapies, both in the adjuvant and neoadjuvant setting. Trastuzumab/Herceptin, 
an antibody that binds to the extracellular domain of HER2, is used in both the adjuvant 
and neoadjuvant setting (20). Lapatinib, a small molecule tyrosine kinase inhibitor of 
HER2, is used to treat women that have been previously treated with trastuzumab, and 
have progressed (21). In addition to the three clinical markers, molecular profiling based 
on gene expression is often used to characterize breast cancer proliferation and to predict 
response to therapy and clinical outcome (17). There are several distinct subtypes of 
breast cancer, originally identified by gene expression profiling. These are luminal breast 
cancers, HER2 enriched breast cancers, and triple negative breast cancers (22). 
Luminal breast cancer, the most common subtype of breast cancer, is similar in 
nature to normal luminal epithelial cells of the breast, typically expressing luminal 
cytokeratin 8, cytokeratin 18, ER and PR (23). Luminal breast cancers are further 
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subdivided into luminal A and luminal B subtypes, with luminal A comprising 40% of 
breast cancer. Luminal A tumors are characterized by increased ER related genes, 
decreased HER2 cluster genes, and decreased proliferation genes (24). Luminal B, on the 
other hand, comprises 20% of breast cancers and are characterized by lower levels of ER 
related genes, expression of HER2 and higher expression of proliferation clusters (25) . 
HER-2 enriched breast cancers comprise 10-15% of breast cancers and are 
characterized by increased levels of HER-2, proliferation gene clusters and decreased 
luminal and basal-like clusters. They are also usually negative for ER and PR (25). 
Triple negative breast cancers include the basal-like and claudin-low cancers, and 
are similar to the basal epithelia of normal breast (22). They lack ER and PR as well as 
HER2. Basal-like subtypes comprise 15-20% of breast cancer, and are characterized by 
the decreased expression of luminal and HER2 gene clusters, increased proliferation, and 
high grade (23). Claudin-low subtype comprises 5-10% of breast cancers. Claudin-low 
subtypes are enriched for the expression of epithelial-mesenchymal transition genes, low 
expression of cell-cell adhesion genes and increased expression of immune response genes 
(26). 
In addition to receptor testing and gene expression profiling, breast cancer is 
further staged using the American Joint Committee on Cancer and the International Union 
for Cancer Control (AJCC-UICC) classification system for tumor, nodes, and metastases 
(TNM).   These are based on information on the tumor size (T), lymph node involvement 
(N) and the presence and absence of distant metastasis (M). Once the TNM status is 
determined, a stage of 0, I, II, III, or IV is assigned, with 0 being in situ, stage I being 
early stage invasive and stage IV being most advanced with distant metastases. In addition 
to TNM classification, grade may be taken into account during staging. Grade is based on 
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the differentiation and proliferation state of breast cancer cells (27). Poorly differentiated 
tumors are associated with worse prognosis. Accordingly, a Grade of 1, 2, or 3 is 
assigned, with Grade 1 tumors being well differentiated, Grade 2 tumors moderately 
differentiated, and Grade 3 tumors looking poorly differentiated (27). 
Thus, breast cancer treatment selection depends on the stage and receptor status of 
the tumor. Women with early stage breast cancer typically undergo primary surgery 
(lumpectomy or mastectomy) to the breast and regional lymph nodes with or without 
radiation therapy (28). Subsequently, adjuvant systemic therapy may be offered based on 
primary tumor characteristics, such as tumor size, grade, number of involved lymph 
nodes, the status of ER and PR, and expression/amplification of HER2. For women with 
locally advanced breast cancer, care consists of therapy employing systemic and regional 
therapy. Patients with locally-advanced breast cancer sometimes receive neoadjuvant 
systemic therapy, with the goal being to induce a tumor response before surgery and 
enable breast conservation (29). Subsequent adjuvant therapy results in long-term 
improved distant disease-free survival and overall survival.  
Targeted therapies also depend on the tumor subtype. Patients with ER/PR+ breast 
cancer receive endocrine therapy to reduce the risk of breast cancer recurrence and breast 
cancer-related mortality (30). The treatment options for ER/PR+ breast cancers are 
selective estrogen receptor modulators such as tamoxifen, aromatase inhibitors and 
fulvestrant. Tamoxifen binds to the ER, preventing estrogen binding, thereby killing 
estrogen dependent tumor cells (31). Tamoxifen, when compared to a control, results in a 
13% absolute reduction in breast cancer recurrence, and 9% reduction in breast cancer 
mortality over 15-years (32). Aromatase inhibitors inactivate aromatase, the enzyme that 
makes estrogen from testosterone, thereby reducing blood estrogen levels in post-
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menopausal women. Generally, premenopausal women are treated with tamoxifen, while 
postmenopausal women are treated with aromatase inhibitors (33). Fulvestrant, which 
inhibits binding of estrogen to ER and kills estrogen dependent cells, is approved for 
treatment of postmenopausal women who have progressed on prior antiestrogen therapy 
(34). Patients with HER2-positive breast cancer also receive treatment with Trastuzumab, 
an antibody that decreases proliferation of HER2 expressing tumor cells (20). 
Trastuzumab reduces the risk of recurrence by 9.5%, and reduces the risk of mortality by 
2% (35). Patients that have progressed while on trastuzumab are subsequently treated with 
lapatinib, a small molecule HER2 inhibitor (36).  
The majority of breast cancer recurrences occur within the first five years of 
diagnosis, particularly with hormone receptor-negative disease. The five-year survival rate 
for those who present with localized cancer is 99%, and 84% for regional disease with 
lymph node involvement. For women presenting with metastatic disease the five-year 
survival rate is a dismal 18% (Figure1.1) (American Cancer Society).  
 
The problem of metastasis 
Metastatic disease is the most dangerous part of breast cancer; >90% of breast 
cancer deaths are due to metastasis (37). The median survival for metastatic breast cancer 
is 18 to 24 months, depending on the subtype of tumor, sites of metastatic involvement, 
and burden of metastatic disease (38). Common sites (and symptoms) of metastatic breast 
cancer include bone (e.g., back or leg pain and fracture), liver (e.g., abdominal pain, 
nausea, jaundice), lungs (e.g., shortness of breath or chronic cough) and brain (e.g., 
headaches, seizures, memory problems or personality changes) (39). Systemic treatment 













Figure 1.1. Survival is significantly lower for women with metastatic breast cancer. 
Five year relative survival upon diagnosis is 99% for localized breast cancer, 84% for 




                                                































survival, alleviate symptoms, and maintain or improve the quality of life (40). Therefore,  
to impact clinical outcomes, we must understand the process of metastasis in order to 
develop new drugs for metastatic breast cancer. 
Tumors develop when normal cells undergo genetic alterations that impact the 
regulated systems for cellular control. Hanahan and Weinberg have described “the 
hallmarks of cancer,” an organizational concept to convey the complexity of tumorgenesis 
(37). These hallmarks include sustained proliferative signaling, evasion of growth 
suppressors, resistance to cell death, replicative immortality, angiogenesis, and invasion 
and metastasis (Figure 1.2) (37). Cancer cells sustain proliferation by activating growth 
factor signaling pathways through mutations or producing ligands that activate their 
cognate receptors (41). Alternatively, mutations downstream of signaling pathways, 
including phosphatidylinositide 3-kinases and mitogen-activated protein kinases pathways 
also allow sustained tumor cell proliferation (42).  
Inactivation of tumor suppressor genes, such as retinoblastoma and tumor protein 
53 removes important checkpoints that prevent cell growth and proliferation (43). During 
tumor progression, tumors release factors such as vascular endothelial growth factor 
(VEGF) that induce sprouting of new blood vessels, sustaining continued tumor growth 
(44). As carcinomas progress, they invade local tissues, and eventually can metastasize to 
distant organs. The mechanisms that drive metastasis are still unclear (37). 
The main cause of breast cancer mortality is metastasis. Although early surgery is 
often the only way to prevent metastasis, this may not be sufficient. Indeed, recent data 
indicate that metastasis can actually occur years prior to diagnosis (45). Klein et al. have 
calculated that the growth of a tumor from initiation to a size of 1 cm, when it can be 






Figure 1.2. The hallmarks of cancer. These are an organizing principle to understand the 
multiple steps of cancer development. Cancer development is fueled by tumor cell 
intrinsic alterations accompanied by tumor microenvironmental adaptations. Tumor 
intrinsic alterations include sustained growth factor signaling, removing tumor 
suppressors, circumventing apoptosis, genetic abnormalities, and metabolic changes. 
These are accompanied a diverse entourage of “normal” cells that create the tumor 
microenvironment. The tumor microenvironment enables angiogenesis, invasion, 




                                                
2 Modified from Hanahan D, and Weinberg RA. Hallmarks of cancer: the next generation. 
















tumor volume doubling time is similar between the primary tumor and the metastatic 
lesion, much of the tumor evolution and metastasis is hypothesized to have occurred prior 
to detected using current imaging tools, requires an average of 12 years (46). Because 
tumor much of the tumor evolution and metastasis is hypothesized to have occurred prior 
to diagnosis (46). Epidemiological data supports this hypothesis, with the median time 
from tumor resection to a diagnosis of metastasis for patients with a < 2 cm tumor being 
35 months versus 20 months for patients with  >5 cm tumor (46). Clinically relevant 
inhibition of metastasis, therefore, may need to focus more on outgrowth rather than initial 
spreading (47). Thus, to prevent metastatic outgrowth, it is critical to understand how cells 
metastasize, and elucidate pathways that convert metastatic microcolonies into overt 
metastases.  
 
The metastatic cascade 
 In 1887, Paget presciently proposed the “seed and soil” hypothesis (48). He 
posited that primary neoplasms (and metastases) consist of both tumor cells and host cells, 
and that metastatic development occurs in specific organs or microenvironments (“soil”), 
which are biologically unique (49). This conceptual leap has been validated by several 
subsequent studies. For example, one such study was in ovarian cancer patients with 
cancer cells growing in the peritoneal cavity as ascites. The ascetic fluid was drained into 
the venous circulation, resulting in palliation with minimal complications. However, it 
allowed the entry of cancer cells into the jugular vein.  Subsequent autopsy findings from 
the patients revealed that the shunts did not increase the risk of metastasis to organs 
outside the peritoneal cavity, despite continuous entry of millions of tumor cells into the 
circulatory system. Surprisingly, metastases to the lung, the first capillary bed 
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encountered, were rare (50). Clinically, ovarian cancer rarely metastasizes to the lung 
(51). This study demonstrates that metastasis is not a passive process of cancer cell 
dissemination, but is an active process that can be deciphered and potentially stopped. 
The past ten years have seen a tremendous effort to understand metastasis (52). 
Metastases are thought to form following a series of events whereby epithelial cells in 
primary tumors: (1) invade locally through surrounding extracellular matrix and stromal 
cell layers, (2) intravasate into blood vessels, (3) survive in the circulation, (4) arrest at 
distant organ sites, (5) extravasate into tissue parenchyma, (6) survive in these foreign 
microenvironments and form micrometastases, and (7) proliferate at metastatic sites, to 
generate clinically detectable lesions (Figure 1.3) (53). Each process is summarized 
briefly in the sections below. 
Local invasion consists of cancer cells invading into the surrounding tumor-
associated stroma and into the adjacent normal tissue parenchyma (52). Mechanistically, 
invasion may occur by integrin-and protease-dependent mesenchymal invasion, or by 
integrin-dependent amoeboid invasion (54). The invading cells encounter stromal 
components, including fibroblasts, endothelial cells, and immune cells (55). These stromal 
cells in turn are able to enhance the aggressive behaviors of carcinoma cells via various 
signaling mechanisms. For example, secretion of interleukin-6 by adipocytes in the 
microenvironment increases breast cancer invasiveness (56). Tumor cell secretion of 
interleukin-4 stimulates tumor-associated macrophage cathepsin protease activity, which 
in turn increases breast cancer invasiveness (57). Many of the pathways that are activated 
during the invasion process are also part of the normal wound healing process. Because of 
the histologic similarities between the tumor microenvironment and wound healing, 














Figure 1.3. The metastatic cascade. During metastatic progression, tumor cells invade 
into the local stroma. They then penetrate blood vessels, and enter into the circulatory 
system, also known as intravasation. They survive in the circulation, and become 
entrapped in distant organs. They then exit into the distant organ, a process called 
extravasation. Proliferation at the distant organ results in macrometastases. Cancer cells 
are red!."
  
                                                
3 Modified from Gupta GP, and Massague  J. Cancer metastasis: building a framework. 
Cell. 2006: 127:679-695 
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Intravasation occurs when tumor cells enter lymphatic or blood vessels (53).  
Intravasation can be significantly enhanced by the tumor microenvironment. For example, 
TGF! enhances mammary cancer intravasation by increasing the ability of tumor cells to 
penetrate blood vessels (59). Tumor-associated macrophages also engage in a positive-
feedback loop with cancer cells, comprised of the reciprocal secretion of epidermal 
growth factor (EGF) and colony-stimulating factor-1 (CSF-1) by macrophages and cancer 
cells, respectively, resulting in intravasation: macrophages are good at getting through 
blood vessels, with cancer cells following (60). 
Survival in the circulation is another critical step for metastasis. Circulating tumor 
cells (CTCs) have been observed in the blood of cancer patients, and can aid in diagnosis 
and drug development (61). In the circulation, CTCs need to survive the stress of matrix 
detachment, the hemodynamic shear forces and escape the immune system. Cancer cells 
evade these stresses, in part, by binding and activating platelets, enabling successful arrest 
at the vessel walls and masking them from immune response (62).  
Extravasation occurs once cancer cells lodge in the vasculature of distant organs, 
whereby CTCs may initiate microcolonies that rupture surrounding blood vessels 
(63). There is evidence suggesting that primary tumors may influence these distant 
microenvironments, allowing for favorable environments for the CTCs. For example, 
secretion of angiopoietin-like-4 (64), upregulation of cyclooxygenase-2 (65) and secretion 
of matrix metalloproteases (66) may disrupt the pulmonary vascular endothelial cell-cell 
junctions to enhance the pulmonary extravasation of breast cancer cells. 
Micrometastasis formation and colonization occurs once cancer cells are in a 
distant organ. Extravasated carcinoma cells must survive in this foreign 
microenvironment, which often differs vastly from the primary tumor site (52). This 
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makes colonization the rate limiting and most difficult step in the metastatic cascade for 
tumor cells (67). Accordingly, occult micrometastases may successfully grow, remaining 
in a “dormant” state for years. This process, called tumor dormancy, results in minimal 
residual disease that can cause eventual relapse (68). The relapse rate for breast cancer 
after 5 years is about 20% (68).  
 
Tumor dormancy 
Tumor dormancy is the pause in cancer progression and the absence of clinical 
symptoms following treatment of the primary lesion (68). Dormancy at new sites may 
occur due to several reasons. First, proliferation may be absent or slowed due to stress 
signals in the new microenvironment, activating growth arrest programs (69,70). Second, 
angiogenesis may be lacking at the new site, preventing expansion of the lesions (71). 
Third, the immune system may keep micrometastases in check (discussed in more detail 
in later sections). Thus, escape from dormancy may be accomplished by alterations in the 
cancer cells that allow proliferation or prevent apoptosis in the new environment, and/or 
activation of signaling pathways that allow escape from the immune system and 
recruitment of blood vessels (68).  
In sum, these observations may explain why CTCs are prevalent in the 
bloodstream of a majority of cancer patients, but only few of them develop into overt 
metastases. Indeed, preclinical studies show that survival in the circulation, arrest at 
distant sites, and extravasation occurs efficiently in different cancer cell types, with more 
than 80% of intravenously injected tumor cells extravasating (72). In contrast, less than 
3% of these cells survive to form micrometastases. Even more striking, the subsequent 
process of metastatic colonization is even more inefficient; less than 0.02% of 
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intravenously injected cells generate macroscopic metastases (72). Thus, it is a 
testament to our current lack of mechanistic knowledge about metastatic outgrowth that, 
even taking into account the inherent inefficiency and difficulty of metastatic 
colonization, there are no approved drugs designed to specifically block metastatic 
outgrowth (73). Instead, systemic cytotoxic agents are standard care in the metastatic 
setting. 
 
Developing therapeutics for metastasis 
Understanding the metastatic process is critical in developing antimetastatic drugs. 
Truly effective antimetastatic therapeutics must prevent the outgrowth of disseminated 
tumor cells, rather than just blocking escape of these cells from the primary tumor (73). 
Unfortunately, existing adjuvant therapies exhibit limited activity against metastatic 
lesions once they are detected, perhaps due to pharmacological or biological barriers (74). 
For example, this lack of efficacy may be related to drug delivery, or by the specific 
features of the target organs (i.e., the blood-brain barrier) (75). Alternatively, this lack of 
efficacy may reflect biological differences between the primary tumors and the metastatic 
lesions that make the latter resistant to therapy (76). 
There are several criteria that candidate genes must satisfy to be considered as 
potential targets for antimetastatic therapy (73). First, their expression should correlate 
with disease-free survival or therapeutic response. Second, the manipulation of these 
genes must impact metastasis in preclinical animal models without causing systemic 
toxicity.  One promising avenue for targeting metastasis is manipulating the signaling 
nodes between tumor cells and the new metastatic microenvironment, because adaptation 
to the new microenvironment is a limiting step in metastasis (as noted above). Tumor 
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microenvironment can comprise vascular and lymphatic endothelial cells, fibroblasts, 
leukocytes, and structural tissues like bone, expanding the possible targets for therapeutic 
intervention (55). Targeting the tumor microenvironment has several advantages (77). 
First, metastatic tumor cells rely on the tumor microenvironment to provide necessary 
signals, cytokines and nutrients. Second, cells of the microenvironment are genetically 
stable, and are thus less likely to become resistant to the drug. Therefore, understanding 
the interactions between the host and tumor cells, especially during the metastatic cascade, 
should yield high value targets for therapeutic targeting. There have been recent successes 
in targeting the tumor microenvironment, specifically in bone metastasis (78). For 
example, bisphosphonates and the antireceptor activator of nuclear factor kappa-B ligand 
antibody, denosumab, slow down bone degradation in breast and lung cancer patients with 
bone metastasis (79). These treatments have significantly improved quality of life for 




Although cancer cells initiate tumors and drive tumor progression, tumors contain 
a diverse entourage of “host” cells, including fibroblasts, innate and adaptive immune 
cells, endothelial cells, and pericytes (55). The numerous interactions that occur between 
epithelial cancer cells and the tumor microenvironment influences both cancer progression 
and metastasis. This makes it clear that the biology of a tumor can best be understood by 




 Increased vessel density is associated with poor prognosis in a wide range of 
human cancers (80). Tumor angiogenesis, the growth of new vessels from preexisting 
vascular beds, is regulated by factors that elicit a proangiogenic effect by stimulating 
perivascular cell proliferation, migration, and tube formation (37). For example, hypoxic 
conditions result in increased secretion of VEGF, resulting in increased blood vessel 
recruitment (81). Important contributors to blood vessel formation are pericytes, which 
provide physical support, stabilization, and prosurvival factors for their associated 
endothelium (82). 
Fibroblasts synthesize and remodel the extracellular matrix (ECM) by producing 
ECM proteins such as collagens and structural proteoglycans, as well as various classes of 
proteolytic enzymes and their inhibitors (83). Moreover, “cancer-associated” fibroblastic 
cells secrete various growth factors that regulate cell proliferation, morphology, and 
survival (83). 
The ECM is an integral part of the tumor microenvironment (84). The ECM 
contains a mixture of fibrillar proteins, glycoproteins, proteoglycans, cytokines, and 
growth factors. It acts as a physical scaffold, facilitating interactions between different cell 
types, and providing survival and differentiation signals (84). Moreover, ECM proteins 
facilitate cell migration and invasion. For example, the ECM protein periostin may 
enhance metastasis by concentrating Wnt ligands in the metastatic niche (85). Tenascin C, 
another ECM protein, may also enhance metastasis by signaling through the Notch 
signaling pathway and supporting metastasis-initiating cells (86). 
Immune cells, including granulocytes, dendritic cells, macrophages, natural killer 
cells, mast cells, and lymphocytes, are prominent components of neoplastic tissues (37). 
They are important mediators of tumorgenesis, paradoxically acting in both an antitumor 
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and a protumor fashion (87). Immune cells release multiple factors that regulate cell 
proliferation, migration, angiogenesis, and tissue remodeling (37). The role of the immune 
system during cancer progression is addressed in more detail in the next chapter. 
 
Dissertation goal 
The focus of my dissertation is the Macrophage Stimulating Protein (MSP) 
signaling pathway (reviewed in Chapter 3).  Briefly, MSP is a serum protein that is 
released into the blood as an inactive proform and is then activated via cleavage by the 
protease Membrane Serine Protease I (MTSP1 or matriptase) (88). Activated MSP binds 
to its receptor, Macrophage Stimulating I Receptor (MST1R or RON), which is found on 
epithelial cells, osteoclasts, and macrophages (88). 
Ron signaling pathways have been reported to play a role in a wide range of 
human cancer, including breast cancer (88). Mouse models where Ron is overexpressed 
under the mouse mammary tumor virus (MMTV) promoter resulted in metastasis to the 
liver and/or lungs (89). On the other hand, overexpressing MSP in the same model results 
in a broader range of metastasis, including to lung, lymphatics, bone and spleen (90). 
Furthermore, MSP-induced bone metastases in the mice were osteolytic, similar to human 
breast cancer patients (90). In human breast cancer patients, co-overexpression of MSP, its 
activating enzyme matriptase, and Ron (collectively referred to as MSP/matriptase/Ron) is 
a significant independent prognostic factor for metastasis. Importantly, overexpression of 
MSP or Ron mRNA alone did not significantly correlate with patient outcome (90).  
These observations have led to the question that my dissertation has attempted to 
resolve. Specifically, how can apparent activation of the same pathway result in different 
ranges of metastatic phenotypes? Our hypothesis was that Ron function in metastasis of 
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breast cancer could be largely ligand-dependent, even when the receptor is 
overexpressed. Thus, instead of MSP/Ron signaling in tumor cells causing invasion, 
metastasis and migration, MSP/Ron signaling may be acting on macrophages, causing 
changes in the tumor microenvironment that facilitate the increase in metastasis. The 
tumor microenvironment has been shown to play an instrumental role in tumor 
progression (Chapter 3).  
To resolve the role that MSP/Ron signaling has during metastasis, we utilized a 
genetic mouse model of metastasis. My dissertation has uncovered that MSP/Ron 
signaling suppresses CD8+ T cells, enabling metastasis (Chapter 4). This finding has 
generated new questions about the how MSP/Ron signaling suppressed the immune 
system, both in the normal setting and pathological settings (Chapter 5).  
In summary, the most challenging aspect of breast cancer is metastasis. There is an 
urgent need for new treatments to prevent metastatic outgrowth. Multiple interactions 
between tumor cells and stromal cells play an integral role in metastasis. Thus, it is 
important to understand tumor-stroma interactions during metastasis, in order to develop 
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INTRODUCTION TO IMMUNOLOGY 




The immune system functions to defend the body against a wide variety of 
external and internal pathogenic events, including cancer. The immune system is broadly 
divided into innate and adaptive immunity. I will discuss the general function of each 
group, followed by a section on tumor immunology. 
 
The innate immune system 
The innate immune system defends the host from infection in a nonspecific 
manner (1). Innate immunity does not confer long-lasting or protective immunity to the 
host. Accordingly, the innate immune system produces cytokines and chemokines that 
recruit other immune cells to sites of infection, clears dead cells and pathogens by 
phagocytosis, and activates adaptive immunity through antigen-presentation (1,2). The 
innate immune system consists of neutrophils, eosinophils, natural killer (NK) cells, 
dendritic cells (DC) and macrophages (M").  
Neutrophils are polymorphonuclear cells that are among the first responders to 
sites of infection (3). They have various receptors, like complement receptors and 
interferon gamma receptors, that enable them to sense chemical gradients as they migrate 
to sites of infection (4). At the sites of infection, neutrophils release cytokines that recruit 
other immune cells and also clear pathogens by phagocytosis (5). Neutrophil deficiency 
leads to increased susceptibility to invasive bacterial infections and fungal infections (6,7). 
Neutrophils make up a significant portion of the tumor microenvironment (8), and have 
been reported to contribute to tumor development by producing protumor chemokines 
such as interleukin 8 (9) and hepatocyte growth factor (10). 
Eosinophils are leukocytes that are involved in diverse inflammatory responses 
(11). For example, they are important mediators of immunity to parasites, viral infections 
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and allergies (12). They produce reactive oxygen species, cytokines such as interleukin-6 
and interleukin-1, and growth factors such as vascular epithelial growth factor (VEGF) 
(11). Eosinophil-deficient mice are susceptible to helminthic infections (13). Tumor-
associated infiltration of eosinophil cells is a favorable prognostic factor (14,15), perhaps 
due to their toxic granules, which they release following activation (16). 
NK cells are cytotoxic lymphocytes that do not express B and T cell antigen- 
receptors and cannot form memory cells (17). However, like CD8+ T cells (discussed in 
the adaptive immunity section), their main function is to kill infected cells and tumor cells 
with cell-mediated cytotoxicity (18). NK cells release cytotoxic proteins, such as 
granzymes and perforin, when they come in contact with a target cell (19). Additionally, 
NK cells also cause antibody-dependent cell mediated cytotoxicity, using their CD16 
receptors to recognize immunoglobulin G (IgG) antibodies that bind to antigens (20). Loss 
of NK cell function is associated with recurrent viral and bacterial infections (21). 
Decreased activity of NK cells in human cancer patients is associated with increased 
cancer risk (22), demonstrating that NK cells play a role in tumor immune-surveillance by 
inducing tumor cell death (23). 
The main function of DCs is to process and present antigens to T lymphocytes 
(24). DCs are the most potent antigen presenting cells (APCs) for T cells, expressing more 
antigen peptide–major histocompatibility complexes (MHC) structures for longer periods 
of time when compared to the other professional APCs (B cells and macrophages) (25). 
Immature DCs are attracted to areas of inflammation, where they ingest antigens (26,27). 
Once captured, the antigens are processed and presented to T cells via MHC molecules 
(28). In addition to presenting antigens, DCs use their cell surface receptors, CD80 and 
CD86, to stimulate T cell proliferation and activation (29). Loss of DCs increases 
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susceptibility to viral infections such as lymphocytic choriomeningitis virus (LCMV), 
bacterial infections such as Listeria and parasitic infections such as Plasmodium (30). 
Within the tumor microenvironment, DCs can be immunosuppressive and/or angiogenic, 
and express low levels of costimulatory molecules such as CD80 and CD86 (31) or 
angiogenic factors such as VEGF (32), respectively. 
M"s are functionally diverse cells, and play a role in multiple aspects of biology, 
including development, homeostasis, and immune response (33). M"s can phagocytose 
and destroy particulate material, and subsequently present antigens to T cells (33). M"s 
have surface receptors for binding particulate antigens, including receptors for certain 
sugars (e.g., mannose) and for bacterial lipopolysaccharides (via interaction with LPS-
binding protein) (34). M"s fragment, crystallizable receptors (FcRs) and complement 
receptors enable them to bind antigens that have been coated (opsonized) with either IgG 
antibodies (35) or C3b complement protein (36), respectively. M"s also rapidly clear 
apoptotic cells, due to their receptors for phosphatidylserine that is expressed on the outer 
surface of apoptotic cells (33). Loss of M", for example through mutation in macrophage 
colony stimulating factor (M-CSF), results in osteopetrotic mice that lack osteoclasts 
(op/op mice) and are more susceptible to bacterial infection (37). M"s play multiple roles 
in the tumor microenvironment (38); from stimulating tumor cell migration (39), to 
inducing angiogenesis (40) to suppressing the antitumor response (41).  
 
The adaptive immune system 
Adaptive immunity is an antigen-specific defense mechanism that is designed to 
remove pathogens or cells expressing a specific antigen. Adaptive immunity is 
characterized by somatic hypermutations and variable, diverse and joining (VDJ) 
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recombination that allows a vast number of different antigen receptors (42). During 
adaptive immunity, DCs and M"s present antigens to antigen-receptors on lymphocytes 
(discussed in the following section). This results in activation and proliferation of antigen-
specific lymphocytes, culminating in production of pathogen specific antibodies, cytotoxic 
T lymphocytes, as well as cytokine production (43). The adaptive immune system 
comprises B cells and T cells. 
B cells, also known as humoral immunity, produce antibodies. B cells express a B 
cell receptor (BCR), and binding of a matching antigen with the BCR results in B cell 
activation (44). B cells recognize and bind to antigen directly, in contrast to T cells that 
recognize short peptide fragments of protein antigens (45). An activated B cell 
differentiates into a plasma cell that secretes specific antibodies. These antibodies bind to 
antigens, which opsonize them for recognition by innate immune cells (46) . B cells have 
been reported to infiltrate the tumor microenvironment (47), where they regulate tumor 
development by secretion of proinflammatory cytokines, such as IL-10 and TGF! (48), 
inhibition of CD8+ T cell activity (48), and recruiting and activating innate immune cells 
(49). 
T cells circulate in the bloodstream and lymphatic system, and are responsible for 
regulating the activity of other immune cells or directly kill infected or malignant cells 
(50). A key feature of T cells is that they cannot recognize antigens in their native form, 
but only when they are presented on the surface of APCs. The antigen receptors of T cells 
interact with peptides derived from the degradation and processing of foreign antigenic 
proteins (51). These peptides are bound MHC molecules on the surface of APCs. There 
are two types of MHC molecules, MHC class I and class II, which present antigen 
peptides to CD8+ and CD4+ T cells, respectively (28). 
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As alluded to previously, T cell receptors recognize antigenic peptides that are 
associated with MHC molecules on APCs. APCs internalize antigens, process them into 
peptides, and load the peptides onto MHC I or MHC II molecules, a process called antigen 
presentation (28). Exogenous and endogenous antigens are processed and presented to T 
cells by different mechanisms (Figure 2.1). Exogenous antigens (e.g., bacteria) are 
ingested by APCs via phagocytosis or pinocytosis. Subsequently, they are degraded into 
peptide fragments in the lysosome (52). The peptide fragments are loaded onto MHC II 
molecules, where they are recognized by CD4+ T cells (53). On the other hand, 
endogenous antigens are generated within a cell (e.g., tumor antigens) by proteasomal 
degradation (54). Subsequently, the peptides are transported to the endoplasmic reticulum, 
where they are loaded onto MHC I molecules, where they are recognized by CD8+ T cells 
(28,54). However, APCs can also present exogenous antigens via MHC I molecules to 
stimulate CD8+ T cells, a process called cross-presentation (55). Cross-presentation may 
occur when an intracellular pathogen or tumor does not affect APCs, or the endogenous 
MHC I pathway is compromised. Thus, APCs take up the exogenous antigen, and load it 
unto MHC I molecules. Although the exact mechanism is unclear (56) , CD8+  T cells 
activated in this manner are called cross-primed, and play important roles for immune 
defense against viruses and tumors (57).  
CD4+ T, or helper T (TH) cells, facilitate the immune response mainly by 
stimulating other cells of the immune system. Accordingly, they stimulate B cells to 
become activated and to secrete antibodies, and cause macrophages to become more 
effective at killing pathogens (58). Depending on the cytokine expression profile of TH 
cells, they are further subdivided into two groups (59). TH1 cells secrete cytokines (e.g. 







Figure 2.1. Antigen presentation. Antigens are processed and presented to T cells by 
several mechanisms. Exogenous presentation occurs when an antigen-presenting cell 
processes an extracellular antigen and presents it to CD4+T cells via the MHC II molecule. 
Endogenous presentation occurs when antigens that are generated within a cell (e.g., 
tumor antigens in any infected cell) are processed and presented to CD8+ T cell via  MHC 
I molecules. Cross-presentation occurs when extracellular antigen is processed by an 







                                                
1Modified from Germonprez P, Valladeau J, Zitvogel L, Thery C, and Amigorena S. Antigen presentation 
and T cell stimulation by dendritic cells. Annu. Rev. Immunol. 2002; 20;621-67 
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activating CD8+ T cells (see below) and M"s, whereas the cytokines produced by TH2 
cells (e.g., interleukin 4 and interleukin 10) primarily stimulate antibody production by B 
cells (60). 
CD8+ T cells provide defense against viral, bacterial, protozoal infections and 
tumorgenesis (43). Naïve CD8+ T cells reside secondary lymphoid tissues, such as lymph 
nodes and spleen (61), where they are activated by APCs. CD8+ T cells recognize 
processed antigen presented on MHC molecules via the T cell receptor (TCR) (51). A 
naïve T lymphocyte requires a series of signals to become an effector cell (Figure 2.2) 
(62). The first signal occurs when the TCR of the naïve T lymphocyte directly interacts 
with the antigen peptide bound to the MHC molecule on an APC (Signal 1) (45) . The 
second signal for activation comes from interactions between the APC and T cell via co-
stimulatory molecules such as CD80 and CD86 (on APCs), which bind to CD28 on the T 
cell surface (Signal 2) (63–65). If this costimulatory signaling fails to occur, the T 
lymphocyte will not become activated and becomes anergic, a condition where the T cell 
is functionally inactive but still alive (66), a control mechanism that prevents 
inappropriate T cell activation. The third signal involves inflammatory cytokine signaling 
by APCs, leading to robust T-cell activation and proliferation (Signal 3) (67,68).  
Antigen uptake in the absence of inflammatory signals renders phenotypically 
immature APCs that express low levels of MHC molecules and costimulatory molecules, 
leading to T-cell tolerance (69). Thus, to achieve maximal expansion, CD8+ T cells 
integrate multiple signals. These include signaling from the TCR, costimulatory signals, 
and inflammatory cytokines such as IL-12. Moreover, many members of the tumor 
necrosis factor receptor (TNFR) family on APCs also deliver important costimulatory 







Figure 2.2. T cell activation. Activation of naïve CD8+ T cells requires three signals. 
Signal one occurs when the T cell receptor recognized a peptide in the MHC molecules. 
Signal two involves the binding of costimulatory molecules CD80 and CD86 on APCs by 
CD28 on CD8+ T cell. This results in extensive proliferation. Signal three occurs when 












                                                
5 Modified from Curtsinger, JM, Mescher MF. Inflammatory cytokines as a third signal for T cell activation. 
Curr. Opin. Immunol. 2010; 22:333-40 
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proliferating and enter into peripheral tissues.  
As mentioned above, CD8+ T cells are specifically activated following binding to 
MHC I molecules, either on APCs or other “host” cells, such as infected or transformed 
epithelial cells. Peptides that are derived from intracellular abnormalities, such as viral 
proteins from infected cells are processed and presented on the surface of MHC I 
molecules, making the presenting cell a target for CD8+ T cell killing (43).  Alternatively, 
CD4+ T cells can activate CD8+ T cells (71). In this process, APCs present peptides in the 
context of MHC class II molecules to CD4+ T cells. The interaction between the CD4+ T 
cell and the APC induces transient expression of CD40 ligand by the CD4+ T cell. 
Binding of CD40 ligand to CD40 on the same APC enables the APC to present peptides in 
MHC class I in order to specifically activate CD8+ T cells (72,73).  
To activate CD8+ T cells, antigen-presenting cells undergo a series of steps. 
Danger signals from pathogens transform DCs and M"s into efficient APCs and robust T 
cell activators (74). Particulate and soluble antigens are efficiently internalized by 
phagocytosis and macropinocytosis, respectively. Phagocytosis is generally receptor 
mediated, whereas macropinocytosis is a cytoskeleton-dependent type of fluid-phase 
endocytosis (75). Phagocytosis is a major route for antigen uptake and presentation, and is 
mediated by complement receptors, CD14, integrins, and serine/arginine rich family 
members (56). Experimentally, forcing internalization of antigen by phagocytosis strongly 
increases the efficiency of cross presentation, or the presentation of extracellular antigens 
via MHC-class I molecules (76). Physiologically, phagocytosis of apoptotic cells also 
results in efficient cross presentation of antigens (28). In addition FcR-mediated uptake of 
immune complexes, opsonized liposomes, or opsonized dead cells promote efficient cross 
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presentation. The cross-presented antigen can be acquired in several different forms 
including deoxyribonucleic acid, ribonucleic acid, or peptides (77–79).  
Once activated, there are several mechanisms of CD8+ T cell mediated 
cytotoxicity (80). These include granule-mediated apoptosis, Fas-mediated apoptosis and 
TNF-#-mediated apoptosis.  Granule-dependent apoptosis occurs when preformed 
granules or lysosomes of the cytotoxic cell are released upon contact with the target cell 
(81). Lytic molecules such as perforin, granzymes (Grz), and granulysin then come into 
contact with the target cell. Perforin polymerizes on the target cell membrane, forming a 
pore through which Grz-A, Grz-B, and granulysin enter (82). These proteins form a 
complex with mannose-6-phosphate receptor, and are then internalized and released into 
the cytoplasm (83). Granzymes activate caspase 3, resulting in fragmentation of the DNA, 
nuclear membrane and cytoskeleton. Granzymes also cleave Bid, which induces 
cytochrome C release from mitochondria, causing activation of caspase 9 and 
mitochondrial-induced apoptosis (19). 
CD8+ T cells can also mediate cytotoxicity by Fas-mediated apoptosis. Fas is a 
member of the Tumor Necrosis Family Receptor (TNFR-1) family (84). CD8+ T cells 
express Fas ligand (FasL), while target cells express Fas receptor (85). Binding of Fas 
with FasL causes trimerization and subsequent recruitment of Fas-associated death 
domain (FADD) proteins (86). Subsequently, FADD recruits caspase 8 or 10, which 
assemble to form the death-inducing complex (86). This activates effector caspases 3,6 or 
7, which cleave DNA or hydrolyze Bid, triggering mitochondrial-mediated apoptosis (87). 
CD8+ T cells can also kill target cells by secreting tumor necrosis factor-# (TNF-
#), a cytokine that induces apoptosis (88). Following binding by TNF-#, the TNFR 
undergoes multimerization to form the death-inducing signaling complex (DISC), 
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signaling downstream through the caspase activation cascade and mitochondria (89). The 
TNF-TNFR complex has also been shown to enhance nicotiniamide adenine dinucleotide 
phosphate (NADPH) oxidase activity, promoting oxidative stress that results in necrotic 
cell death (90). 
 
The immune system and tumor development 
The various mechanisms of CD8+ T cell mediated cytotoxicity that I described are also 
utilized by the immune system to prevent tumor development, using a process called 
immunosurveillance (91). Thus, the immune system can be an extrinsic tumor suppressor. 
Paradoxically, however, the immune system can also act as an extrinsic tumor promoter 
(92). This contradictory role of the immune system has been recently encapsulated under 
the cancer immunoediting hypothesis (Figure 2.3) (93). This hypothesis posits that cancer 
development must take place in the context of dynamic immune processes that control and 
shape the cancer. When normal cells are transformed, they frequently express ligands and 
antigens which innate and adaptive immune cells recognize, resulting in an antitumor 
response (94,95). However, if antitumor immunity is unable to completely eliminate 
transformed cells, the surviving tumor cells enter into the equilibrium phase, where they 
are somewhat, but not completely, resistant to immune- mediated killing (96). The 
adaptive immune system keeps the tumor cells in check, preventing tumor outgrowth 
(97,98). Eventually, however, tumor cells acquire further alterations that result in the 
evasion of the immune system, and progress to clinically detectable lesions (99,100). For 
example, tumor cells downregulate human leukocyte antigen class I antigens (101) and 







Figure 2.3. Cancer immunoediting. Cancer immunoediting consists of three stages: 
elimination, equilibrium, and escape. Elimination occurs when immune cells destroy 
developing tumors. Effective elimination results in a tumor-free host. Equilibrium occurs 
when a cancer cell is not destroyed in the elimination phase. The immune system 
constantly selects for tumor cell variants with increasing capabilities to survive immune 
attack. Escape is the process wherein tumor cells that are resistant to immune attack 
expand in an uncontrolled manner and emerge to cause clinically apparent disease6.  
 
                                                
6 Modified from Dunn GP, Old LJ, Schreiber RD. The immunobiology of cancer immunosurveillance and 
immunoediting. Immunity; 2006; 6;24-37 
      
    
  
  
      
      
  
  
    
































(PDL1) (102). The immune system, at this stage may paradoxically promote tumorgenesis 
(103).  
Although the cancer immunoediting hypothesis is difficult to prove in human 
patients, tumor-infiltrating lymphocytes are reported to be significantly correlated with 
patient survival (104,105). Tumor infiltration by T cells or NK cells has been associated 
with an improved prognosis for a number of different tumor types. Indeed, the type and 
density of lymphocytes infiltrating epithelial tumors such as colorectal (105), ovarian 
(106) and breast cancers (107)  are powerful prognostic indicators. For example, a tumor 
immune signature consisting of CD68high/CD4high/CD8low significantly correlates with 
reduced overall survival of breast cancer patients (107). 
Additional support for the cancer immunoediting hypothesis comes from immune-
manipulated animal models (99). Cells of both the innate and adaptive immune system 
have been shown to be critical for the elimination of cancers. Lymphocyte-
deficient recombination activating gene 1 and 2 (Rag1$/$, Rag2$/$), severe combined 
immunodeficient (SCID), and nude mice all display an increased susceptibility to tumor 
induction after exposure to carcinogens (108–110), and in their normal lifespan 
(111). Moreover, depleting T cells in previously carcinogen-treated mice results in 
sarcomas that rapidly grow at the original site of carcinogen injection, as well as 
metastatic lesions, suggesting that T cells were keeping transformed cells in check (97). 
 Immunity is a significant barrier that metastatic tumor cells must overcome to 
establish metastatic disease. This was dissected in a model using transgenic mice (RET-
AAD) that express the human RET oncogene and a chimeric mouse/human MHC antigen 
(AAD) specifically in melanocytes (112). These mice develop extensive disseminated 
metastases, and depletion of CD8+ T cells in RET-AAD mice significantly accelerated the 
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outgrowth of metastatic lesions to visceral organs (112). In addition, in the mammary 
mouse tumor virus Polyoma Middle T antigen model of breast cancer, the absence of 
CD8+ T cells significantly potentiated metastasis (113). 
Thus, over time, tumors must evolve mechanisms to elude or inhibit the immune 
system (114). These mechanisms can be cell-autonomous adaptations that enable direct 
evasion of the immune system or noncell autonomous manipulations of the 
microenvironment to create an immunosuppressive network (114). Tumor-intrinsic 
changes that allow immune evasion include downregulation of antigen presentation 
(MHC) molecules (115), upregulation of inhibitors of apoptosis (116), or expressing 
inhibitory cell surface molecules (PDL1) that directly kill cytotoxic T cells (117). 
Additionally, tumor cells secrete various factors, such as TGF-! (118) and arginase (119), 
which can remodel the tumor environment, inhibiting effector immune cell functions and 
generating a generally immunosuppressive microenvironment.  
The immunosuppressive tumor microenvironment is comprised of various immune 
cells that not only contribute to suppressing the immune system, but also can directly 
facilitate tumor progression (120,121). Macrophages can promote tumor angiogenesis, 
invasion, intravasation and metastasis in animal models (122). Macrophages can be 
subdivided into two broad categories, depending on their function (123). ‘Classically 
activated’ (M1) macrophages contribute to tumor rejection through TH1-type cytokine 
production and antigen presentation, whereas ‘alternatively activated’ (M2) macrophages 
enhance angiogenesis and remodeling through TH2-type cytokine production (41). Tumor 
associated macrophages (TAMs) have been shown to have M2 characteristics, and are 
associated with poor prognosis (124,125). TAMs secrete cytokines like TGF-! (126) , IL-
10 (127), and platelet derived growth factor (PDGF), which inhibit T cells (128) . 
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Myeloid-derived suppressor cells (MDSCs), which resemble poorly differentiated 
granulocytes (129), are also often increased in tumors. They are immunosuppressive, in 
part through inhibition of T-cell activation (130,131). Type 1 CD4+ T cells (TH1) aid 
CD8+ T cells in tumor rejection (132,133), whereas type 2 CD4+ T cells (TH2) and CD4+ T 
regulatory cells inhibit CD8+ T cells through multiple mechanisms (134,135), including 
expression of cytotoxic T-lymphocyte antigen 4 (CTLA-4), a cell surface molecule that is 
expressed on CD8+ T cells and is a critical inhibitory regulator of T cell expansion (136).  
As mentioned above, CD8+ T cells are the effector cells of the adaptive immune 
system that specifically recognize and destroy cancer cells through perforin- and 
granzyme-mediated apoptosis. However, CD8+ T cells in the tumor microenvironment are 
ineffective in killing tumor cells for reasons that remain largely unknown. This 
ineffectiveness is hypothesized to be due to the heavily immunosuppressive tumor 
microenvironment (137). First, CD8+ T cells stimulation is hindered by the lack of 
positive costimulatory signals and expression of negative costimulatory signals on APCs 
(138,139). Second, there is ample expression of immunosuppressive cytokines like IL-10 
and TGF-! (140–142). Third, tumor cell expression of proapoptotic molecules, such as 
Fas ligand, induces T cell apoptosis (143,144). Fourth, tumors express the tryptophan-
depleting enzyme, indoleamine 2, 3-dioxygenase (IDO), which causes nutritional 
deficiency for T cells, rendering them unable to survive in the tumor microenvironment 
(145,146). Fifth, there is significant accumulation of T regulatory cells, MDSCs, and 
TAMs that all inhibit T cell effector functions (147,148). 
 How tumor-immune cells interact at metastatic sites, and how tumor cells escape 
immune surveillance during metastatic growth, remains largely unknown (149,150). Thus, 
identifying and targeting the key mechanisms by which tumor cells mediate suppression 
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of CD8+ T cells during metastatic outgrowth holds potential as a strategy to reduce or 
prevent escape from dormancy, and thereby block progression of metastasis. 
Disseminated cancer cells are hard to treat, due to biological barriers (e.g., blood-brain 
barrier) and potential genetic drift from the original cancer leading to treatment resistance 
(151).  However, the immune system can efficiently search and specifically prevent tumor 
cells outgrowth. For example TH1 immunity has been reported to prevent cancer 
proliferation by inducing cancer cell senescence through IFN-%- and TNF-# (152). 
In summary, the immune system plays a multifaceted role during cancer 
development and metastasis. The dual role of the immune system, both antagonizing and 
supporting tumor development, suggests that there are multiple pathways that are potential 
therapeutic targets. The recent approvals of ipilimumab, a CTLA-4 inhibitor for metastatic 
melanoma, and sipuleucel-T, a vaccine for prostate cancer, demonstrate the promise of 
harnessing the immune system for cancer therapy. Thus, deciphering the tumor-immune 
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Abstract: Macrophage Stimulating Protein (MSP) is the only known ligand for the receptor tyrosine kinase Ron. The 
MSP/Ron pathway is involved in several important biological processes, including macrophage activity, wound healing, 
and epithelial cell behavior. A role for MSP/Ron in breast cancer has recently been elucidated, wherein this pathway 
regulates tumor growth, angiogenesis, and metastasis. Here, we review the recent literature surrounding MSP/Ron 
function in tumor cells, inflammatory cells, and osteoclasts – cell types that often coexist in breast tumor microenviron-
ments. We discuss the potential implications of MSP/Ron activity occurring concurrently in these cell types on tumor 
progression and metastasis. Lastly, we outline the potential for targeting MSP/Ron as a novel therapy for breast cancer, 
and for other cancer types. 
Keywords: Breast cancer, macrophage stimulating protein, metastasis, MSP, MST1R, osteolysis, Ron, therapeutic target.  
INTRODUCTION 
 Breast cancer has a relatively low case-fatality rate, but 
approximately 20% of women diagnosed with breast cancer 
eventually develop metastatic disease. Because breast cancer 
is highly prevalent and metastatic breast cancer is rarely 
curable, a significant number of women, about 40,600 in the 
U.S. per year, will die of the disease [1]. Although the 
incidence of breast cancer is much higher in women over 50, 
breast cancer is the major cause of death from all reasons in 
women age 35-50 and represents a major health care and 
societal problem.  
 The goal of initial treatment is to reduce the risk of both 
local and systemic recurrence. Initial treatment for localized 
breast cancer is designed to reduce the risk of in-breast and 
regional disease; local recurrence in breast, skin, subcu-
taneous tissues and axilla rarely causes death but often 
results in significant morbidity and can give rise to systemic 
metastases [2]. Local therapy begins with surgery: either 
lumpectomy to remove the tumor from the intact breast, or 
mastectomy. Radiation therapy reduces the risk of local 
recurrence and is almost always recommended after lumpec-
tomy. Radiation is also generally recommended after mastec-
tomy if the tumor is large or involves regional lymph nodes. 
Initial treatment of breast cancer often also includes systemic 
therapy designed to eradicate occult metastatic disease that is 
not clinically evident, but which may eventually cause 
relapse and death. Treatment given in this setting is termed 
“adjuvant therapy” and, because of the near-universal fatality 
of metastatic breast cancer, is recommended for the majority 
of women newly diagnosed with breast cancer in order to 
improve disease-free survival [3].  
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 Systemic therapy for breast cancer may be given either as 
adjuvant therapy or as treatment of metastatic disease, and 
includes hormonal therapy, chemotherapy, and/or biological 
agents. Hormonal therapy is used if the malignant cells exp-
ress estrogen and/or progesterone receptors. Chemotherapy 
of several different classes can be effective in all types of 
breast cancer, independent of hormone receptor expression. 
Targeted therapies used in breast cancer include trastuzu-
mab, a monoclonal antibody approved for use in combina-
tion with chemotherapy for HER2 positive breast cancer, and 
lapatinib, a small molecule used for HER2 positive meta-
static breast cancer. Bevacizumab, a VEGF inhibitor, is also 
approved for use in metastatic breast cancer [3]. Numerous 
other agents are being evaluated as potentially effective adju-
vant therapies, notably bisphosphonates, which are best 
known for blockade of osteoclast function. Various bisphos-
phonates are in late-phase clinical trials and may reduce the 
risk not only of skeletal metastases, but visceral metastases 
as well [4]. 
 Patients with metastatic breast cancer have a median 
survival of approximately two years [5]. Women with hor-
mone-sensitive metastases limited to bone and soft tissue 
have on average a longer survival, while those with exten-
sive parenchymal organ involvement usually have a shorter 
survival, particularly if the tumor does not express hormone 
receptors or HER2. These latter tumors are aggressive, and 
there are no targeted therapies available for this subtype of 
breast cancer. Clearly, there is a need for new therapies with 
greater efficacy against this disease, and a particular need for 
therapies that might reduce or prevent the growth of meta-
static lesions. Targeted therapies are generally less toxic than 
other anti-cancer agents and, when effective, are invaluable 
in achieving the goal of treatment of metastatic breast 
cancer: to achieve disease control while avoiding toxicity 
due to therapy. Here, we discuss the exciting potential for a 
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THE MET/RON FAMILY OF RECEPTOR TYROSINE 
KINASES 
 The receptor tyrosine kinase Ron (also known as human 
MST1R, for macrophage stimulating 1 receptor, and as 
murine Stk1, for stem cell kinase 1) is the cell surface recep-
tor for macrophage stimulating protein (MSP; also known as 
MST1, for macrophage stimulating 1, and as HGFL, for 
hepatocyte growth factor-like). In humans, Ron is one of 
only two members of a distinct receptor tyrosine kinase 
(RTK) family that also includes Met. The highest amino acid 
identity between Ron and Met is located within the kinase 
domain (63% identity); the other regions are not highly 
conserved (34% overall). The respective ligands for Ron and 
Met are also similar; MSP is 45% identical to hepatocyte 
growth factor (HGF), the Met ligand. Both ligands are glyco-
proteins that are secreted as inactive single-chain peptides 
and are proteolytically processed into active, disulfide-linked 
!/" heterodimers [6]. HGF binds and activates Met and MSP 
binds and activates Ron [7-9]; although there is crosstalk 
between Ron and Met intracellular signaling [10, 11] the 
ligands and receptors are not interchangeable [12]. 
 Like their ligands, Met and Ron are cleaved disulfide-
linked heterodimers. The mature receptors consist of extra-
cellular ! and " chains, involved in ligand binding, and the 
intracellular portion of the " chain, which is responsible for 
signaling. Binding of ligand causes receptor homodimeriza-
tion and phosphorylation of two tyrosine residues within the 
catalytic site, which regulates kinase activity [8, 13]. Activa-
tion of kinase activity results in phosphorylation of the 
carboxy-terminal docking site of the receptor. The docking 
site is essential for downstream signaling through direct and 
indirect binding of SH2 domain-containing adaptor proteins 
such as Grb2, PI3K, and Src [14]. Ron and Met are both 
expressed in a variety of tissues during development and, in 
adults, are expressed mainly on epithelial cells and in the 
nervous system. However, Ron is also highly expressed on 
adult macrophages and osteoclasts. 
 Although the signaling pathways that are activated by 
Ron and Met are similar, they culminate in related, yet 
distinct, cellular functions. Both are known to induce 
“scattering,” a phenomenon in which cells detach from one 
another and migrate away from the central colony [10, 15, 
16]; both promote proliferation through the MAPK pathway 
and survival through both MAPK and PI3K/AKT pathways 
[17-19]; and both have the ability to promote an epithelial-
mesenchymal transition, albeit in distinct situations [20, 21]. 
However, a major effect of MSP/Ron signaling is on the 
motility and activation of macrophages – a function clearly 
divergent from that of Met. 
 Terminally differentiated macrophages express Ron and 
were first noted to respond to MSP by rapidly altering their 
shape and increasing chemotactic and phagocytic ability [22, 
23]. More recently, it has been realized that MSP/Ron also 
plays a critical role in attenuation of the inflammatory 
response. Mice lacking Ron activity display defects in the 
inflammatory process, most notably the inability to downre-
gulate TNF! and nitric oxide production in response to 
infection or injury [24-27]. Thus, MSP/Ron signaling plays a 
dual role in regulating inflammation: initial stimulation of 
chemotaxis and phagocytosis – important features of “classi-
cal” macrophage activation - and, more critically, resolution 
of the inflammatory response by promotion of the “alterna-
tively activated” macrophage state (discussed in more detail 
below). 
 MSP belongs to a group of kringle domain-containing 
proteins that diverged from an ancient family of serine pro-
teases involved in blood coagulation and fibrinolysis [28]. 
Amino acid substitutions in the catalytic domain during 
evolution rendered MSP inactive as a protease, although it 
retained the feature of being cleaved and activated by other 
serine proteases. Such cleavage is, in fact, required for the 
conversion of pro-MSP to the mature, active form of MSP 
that can bind and activate Ron. 
 Activation of pro-MSP was originally discovered in 
wound exudates, where it resulted in stimulation of macro-
phage activity [23]. A serine protease responsible for activa-
ting pro-MSP was localized to macrophage membranes [29] 
and later identified as matriptase [30]. However, other 
proteases, such as hepatocyte growth factor activator, also 
appear to cleave and activate pro-MSP in vivo [31]. Pro-MSP 
is predominantly secreted from the liver, and exists in the 
blood plasma in its biologically inactive form at a concen-
tration of about 5nM, and is thus poised to initiate Ron 
signaling upon cleavage [23]. 
 Functional consequences of MSP/Ron signaling are not 
limited to macrophages or the inflammatory process. Ron, 
like Met, is upregulated in many types of epithelial cancer, 
and they are occasionally co-upregulated [32, 33]. Although 
the role of Met in cancer has been investigated for more than 
20 years, culminating in development of multiple targeted 
therapies now in clinical trials (for a recent review, see [34]), 
Ron has more recently been recognized as a major player in 
progression of human epithelial cancers. This report focuses 
on the significance of the MSP/Ron pathway in breast 
cancer, and the ensuing opportunities for therapeutic 
intervention. 
RON EXPRESSION AND FUNCTION IN BREAST 
CANCER 
 Ron is expressed at very low levels in normal human 
breast epithelium, but becomes overexpressed in a large 
proportion of breast tumors (Table 1). Interestingly, Ron 
mutation is not associated with breast cancer, suggesting that 
overexpression of the wild type protein is sufficient to 
contribute to tumor development or progression. The reason 
for overexpression has not yet been established. Both MSP 
and Ron are located on chromosome 3p21.31, and the 3p21 
region is often altered in cancer. Specifically, 3p21 under-
goes both loss of heterozygosity [35] and amplification in 
various tumors and cancer cell lines [36, 37]. This region 
was amplified in 15-42% of lung, renal, and breast cancers 
examined [36], which suggests that amplification could 
contribute to MSP and/or Ron overexpression in breast 
cancer. Consistent with this, MSP is also overexpressed by 
up to ~20% of early stage human breast tumors [38]. 
 Mouse models have been instrumental for elucidating the 
contribution of Ron signaling to breast cancer. When 
overexpressed under the mouse mammary tumor virus 
(MMTV) promoter, Ron caused mammary hyperplasia by 12 
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in 100% of female mice [39]. Tumors initiated by Ron 
exhibited spontaneous metastasis to liver and/or lung in 
~90% of animals, which is remarkable given the relatively 
limited metastatic potential of other transgenic mouse 
models of breast cancer [40]. Confirmation that the Ron 
pathway is a significant contributor to breast tumor meta-
stasis was obtained by examining 457 breast cancers from 
two independent patient cohorts [38]. In these studies, co-
overexpression of MSP, its activating enzyme matriptase, 
and Ron (collectively referred to as MSP/matriptase/Ron) 
was used as a surrogate indicator of Ron signaling activity, 
and was a significant independent prognostic factor for 
metastasis and reduced survival. Importantly, overexpression 
of MSP or Ron mRNA alone did not significantly correlate 
with patient outcome, suggesting that Ron function in 
metastasis of breast cancer could be largely ligand-depen-
dent, even when the receptor is overexpressed. Indeed, 
activation of Ron by overexpression of MSP in a mouse 
model of mammary cancer (transgenic mice expressing the 
polyomavirus middle T antigen under the mouse mammary 
tumor virus promoter; MMTV-PyMT [41]) was sufficient to 
cause spontaneous metastasis to lung, lymphatics, and bone. 
Patients whose tumors expressed MSP/matriptase/Ron also 
exhibited significantly more metastasis to lung, liver, brain, 
and bone (bone was the most frequent site of metastasis). 
Furthermore, MSP-induced bone metastases in the mice 
were osteolytic, as they are in human breast cancer patients, 
and appear to be the first example of spontaneous metastasis 
of a primary (non cell line-derived) tumor from the 
mammary gland to the bone in mice [38]. Thus, MSP/Ron 
activity exerts a gain-of-function effect in breast cancer, 
promoting tumor metastasis to clinically relevant sites. 
OPPORTUNITIES FOR RON INHIBITOR THERAPY 
IN BREAST CANCER 
 Consistent with the knowledge that breast cancer is a 
complex and remarkably heterogenous disease, single agent 
targeted therapy has generally not been effective long term, 
even in combination with standard chemotherapy. This is 
particularly true for metastatic breast cancer, which is still 
considered incurable [42]. Our ever-increasing understand-
ing of mechanisms involved in tumor progression suggests 
that the ability to simultaneously abrogate several indepen-
dent processes that are critical for cancer progression would 
hold great promise for new therapeutic approaches. 
 It is now realized that many of the processes that contri-
bute to tumor progression and metastasis are not actually 
intrinsic to the tumor cells. Rather, the tumor microenviron-
ment plays a key role in critical processes such as angioge-
nesis [43], growth factor production [44], tumor inflamma-
tion and immunoediting [45], invasion and intravasation 
[46], as well as modifying the metastatic site to create a 
hospitable environment [47]. In fact, it has become clear that 
tumor progression and metastasis in mouse models can be 
severely restricted or even eliminated by limiting tumor 
inflammation [48, 49]. 
 Data obtained in vivo using sophisticated mouse models 
and primary human breast cancer specimens strongly suggest 
that the Ron pathway is an exciting new target for therapy 
against solid tumors. MSP/Ron not only plays a causal role 
in tumor development and progression, but also plays a 
critical role in the type of inflammation that is known to 
occur in tumor microenvironments [50, 51]; this is discussed 
in detail below. Based on the known function of Ron in 
tumor cells, macrophages and osteoclasts, we suggest that 
Ron inhibition would simultaneously block essential 
processes both intrinsic and extrinsic to the tumor cells: 
tumor growth and angiogenesis, promotion of metastasis by 
‘alternatively activated’ macrophages, promotion of the 
wound healing process, and osteolysis due to breast cancer 
bone metastasis. The specific functions of Ron in each of 
these processes in the ‘normal’ state are discussed in detail 
below, followed by a discussion of the implications for Ron 
activity in the setting of cancer.  
TUMOR-INTRINSIC ACTIVITIES: MSP/RON IN 
TUMOR GROWTH AND ANGIOGENESIS 
 Investigation of Ron activity in epithelial cancer cell 
lines has revealed roles in cell proliferation, survival, migra-
tion, and epithelial-mesenchymal transition [15, 52-54]. 
Selective Ron inhibitors have been generated and were 
reported to affect these processes, indicating that blockade of 
Ron function is achievable at least in certain settings [18, 
55]. 
 As described above, gain of function studies in mouse 
models have shown that activation of Ron through either 
overexpression of MSP [38] or overexpression of Ron [39] 
was sufficient to increase tumor growth as well as both the 
frequency and tissue tropism of metastasis in mice, and 
overexpression of MSP/matriptase/Ron significantly correla-
ted with increased metastasis and death in breast cancer 
patients [38]. 
 Conversely, loss of Ron function has been demonstrated 
to affect tumor growth, angiogenesis, and metastasis in a 
mouse model of breast cancer. Mice lacking the tyrosine 
kinase domain of Ron (Ron TK-/- [56]) were crossed to 
MMTV-PyMT mice, which resulted in decreased mammary 
tumor growth and reduced metastasis to lung – the only site 
of metastasis in the MMTV-PyMT model. This effect 
occurred in parallel with decreased vasculature and increased 
apoptosis in the tumors [57]. Selective Ron inhibitors have 
also shown some efficacy in xenograft models for other 
types of cancer (see below). Together, these data suggest that 
abrogation of Ron activity can impair tumor growth and 
reduce the likelihood of metastasis, and that pre-clinical 
studies using Ron inhibitors have shown promising results. 
TUMOR-EXTRINSIC ACTIVITIES: MSP/RON IN 
MACROPHAGE ACTIVITY 
 Ron is expressed on terminally differentiated resident 
macrophages, but not on mononuclear phagocytes or circu-
lating monocytes; Ron is upregulated during macrophage 
differentiation [58]. Ron is expressed on many different 
types of resident macrophages including alveolar macro-
phages, microglia, peritoneal macrophages, and dermal 
macrophages from either normal or wounded skin [23, 59, 
60]. 
 As suggested by its name, MSP does function to stimu-
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macrophages to undergo chemotaxis; stimulation of Ron by 
MSP leads to rapid changes in cell shape and motility [30, 
61]. MSP/Ron activity also promotes rapid phagocytosis of 
C3bi coated erythrocytes via complement receptor 3 [62]. 
 Consistent with its function in macrophage stimulation, 
in vivo experiments demonstrate that the Ron pathway is 
important in protection against Gram-positive bacteria. 
When Ron -/- mice were challenged with Listeria monocyto-
genes they showed increased bacterial burden and increased 
susceptibility to the infection - a phenotype similar to that of 
interferon-gamma (IFN ! ") knockout mice and tumor necrosis 
factor-alpha (TNF-") knockout mice. Lack of Ron function 
may manifest itself in the inability of macrophages to 
efficiently eliminate the bacteria, as rapid clearance by 
macrophages via the complement receptor is known to be 
essential in preventing Listeria infections [62].  
 Studies of MSP/Ron signaling in macrophages indicate 
that, although the Ron pathway is involved in macrophage 
activation and protection from particular microorganisms, it 
is critical for resolution of inflammation in many models. 
Mice lacking Ron activity are viable and fertile but have 
noteworthy defects in macrophage function; Ron is nece-
ssary to limit inflammatory responses [56, 63]. Peritoneal 
macrophages isolated from Ron deficient mice produce 
increased levels of nitric oxide in response to lipopoly-
saccharide (LPS) stimulation, and when Ron TK-/- mice are 
challenged with sub-lethal doses of LPS, they are more 
susceptible to LPS-induced endotoxic shock [56]. 
 The mechanisms by which MSP/Ron signaling functions 
to resolve inflammation are elegantly studied. One important 
function of Ron is to downregulate interleukin 12 (IL-12) 
production in macrophages. The inability of Ron TK-/- mice 
to downregulate IL-12 leads to increased IFN-! production 
by natural killer cells, and a prolonged inflammatory 
reaction [50]. In vitro, MSP is sufficient to polarize macro-
phages from the “classically activated” to the “alternatively 
activated” state [64] (also known as the M1 and M2 states, 
respectively, and further described below). MSP/RON 
signaling also suppresses inflammation through several other 
routes: activation of suppressors of cytokine signaling, 
down-regulation of IFN- , reduction of major histocom-
patability complex class II
 
cell surface expression, and 
reduction of IFN- -induced
 
STAT1 phosphorylation [50]; 
downregulation of inducible nitric oxide synthase (iNOS) 
[64]; increased production of the anti-inflammatory cytokine 
IL-10 [65]; and downregulation of cyclooxygenase-2 (COX-
2) expression through inactivation of Nuclear Factor kappa B 
(NFkB) [66]. 
 Taken together, the published data indicate that the 
MSP/Ron pathway plays a dual role in inflammation: a role 
in initial macrophage activation, as well as an important role 
in downregulating the inflammatory response. Ron activity 
results in increased migration of macrophages to sites of 
infection, and stimulates phagocytosis early in the infection 
process. Later, Ron is required to resolve inflammation by 
downregulating iNOS and IL-12 and by upregulating IL-10. 
Still, much is to be learned: the different roles for Ron 
signaling in infections elicited by gram-positive versus 
gram-negative bacteria indicate that MSP/Ron function is 
context dependent, and the interaction of MSP-stimulated 
macrophages with cells of the acquired immune system is 
yet to be discovered.  
AN INTERSECTION OF INSTRINSIC AND EXTRIN-
SIC FACTORS: MSP/RON IN WOUND HEALING 
 Skin wound repair is essential for tissue homeostasis and 
involves three phases: inflammation, proliferation, and remo-
deling (for review see [67]). Inflammatory cells play a 
crucial role in the wound healing process. Macrophages 
remove dead tissue, stimulate the growth of new blood 
vessels, regulate fibroblast recruitment, re-growth of the 
epithelium, and remodeling of connective tissue (for review 
see [68]). Classically activated macrophages (M1 macropha-
ges) are present early during the wound healing process and 
function to remove pathogens and stimulate the immune 
response, whereas alternatively activated (M2) macrophages 
predominate later in the repair process. M2 macrophages fail 
to present antigen to T cells, produce minimal amounts of 
pro-inflammatory cytokines and nitric oxide, and are less 
efficient than M1 macrophages at killing microbes. Instead, 
M2 macrophages secrete extracellular matrix (ECM) pro-
teins and polyamines, which influence production of cyto-
kines, inhibit clonal expansion of lymphocytes, and stimulate 
proliferation of epithelial cells [69]. M2 macrophages are 
characterized by downregulation of iNOS and upregulation 
of arginase 1, which metabolizes arginine to urea and 
ornithine. Consequently, there is increased arginase activity 
in experimental rat wounds, along with increased ornithine 
levels [70]. Importantly, MSP/Ron signaling is instrumental 
in the switch from expression of iNOS to expression of 
arginase [64]. 
 Successful wound repair entails resolution of the inflam-
matory response and, as discussed above, MSP is both 
necessary and sufficient to induce M2 macrophage polari-
zation, which assists in attenuation of inflammation. MSP/ 
RON signaling is involved at various steps of the wound 
healing process. In experimental excisional wounds in rats, 
immunostaining revealed both MSP and Ron within the 
wound, where maximum staining occurred between 7 and 21 
days post-wounding [71]. There are also increased levels of 
activated MSP in fluids collected from burn wounds in 
humans, and RON-expressing macrophages are scattered 
throughout the dermis.  
 In addition to resolving inflammation in wounds, Ron 
plays a role in repairing wounded skin. This process, referred 
to as re-epithilialization, involves migration and proliferation 
of epidermal keratinocytes. Cells at the wound margin 
loosen their extracellular matrix (ECM)-cell and cell-cell 
interactions in order to migrate across the wound (for review, 
see [72]. Ron is upregulated by proliferating and differen-
tiated populations of keratinocytes [23], and MSP promotes 
keratinocyte migration in mouse wounds and in wound 
healing assays in vitro. In primary keratinocytes, the 14-3-3 
protein associates with Ron in response to MSP signaling, 
which induces spreading and improved migration on laminin 
5 ECM [73]. It is notable, however, that MSP deficient mice 
do not show any defects in specific skin wound healing 
models [74], suggesting that functional redundancies exist 
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 The role of MSP/Ron in other models of injury has also 
been investigated. In two different models of lung injury, 
Ron proved to be essential for protection from unregulated 
inflammation. When injected with intrapulmonary LPS, mice 
lacking Ron function display increased lung injury and 
damage due to overproduction of nitric oxide and TNF! 
through the NFkB pathway. Again, MSP/Ron function was 
deemed necessary to suppress NFkB activation in vivo [75]. 
In a nickel-induced acute lung injury model, in which mice 
are exposed to aerosolized nickel particles, mice lacking 
RON function exhibited significantly decreased survival 
times compared to control mice. The mice showed increased 
levels of IL-6 and the chemokines Chemokine (C-C motif) 
ligand 2 (CCL2) and Chemokine (C-X-C motif) ligand 12 
(CXCL12), as well as increased serum nitrite levels. These 
effects were commensurate with earlier onset of pulmonary 
inflammation, edema and lethality [76]. Gene expression 
analysis indicated that genes responsible for inflammation, 
edema and lymphocyte function were significantly altered in 
mice lacking Ron activity [77]. 
 Paradoxically, in a model of LPS-induced acute liver 
failure in galactosamine-sensitized mice, RON deficient 
mice are actually protected from liver injury. This finding 
was based on histological analysis as well as serum alanine 
amino transferase levels, and was associated with decreased 
number of liver cells undergoing apoptosis [78].  
 The last three examples of Ron involvement in injury 
indicate that the cytokine milieu and the type of injury likely 
influence the outcome of MSP/Ron signaling. Data from 
mice lacking Ron activity indicate that blocking MSP/Ron 
signaling therapeutically may not adversely affect healing of 
common skin wounds, but could be a concern for life-
threatening infections. An important consideration, however, 
is whether acute loss of Ron function (as would occur with 
therapeutic blockade of Ron signaling) would have different 
effects than the chronic lack of function that develops in 
genetically engineered mice. 
INFLAMMATION AND CANCER: DUAL FUNCTION 
OF MSP/RON? 
 A growing body of evidence supports the idea that 
inflammation contributes to cancer development and prog-
ression (for review, see [45]). The risk of developing cancers 
of the esophagus, colon, pancreas, lung, and gallbladder is 
heightened by the presence of chronic inflammatory dis-
eases. Chronic inflammation, like chronically unhealed 
wounds, is characterized by a prolonged cycle of tissue 
damage, cellular proliferation and tissue repair [79]. The 
inflammatory environment is enriched with macrophages 
that generate high levels of reactive oxygen and nitrogen 
species to fight infection. However, when unregulated, these 
agents can react with DNA and cause mutations in 
proliferating epithelial and stromal cells (for review, see 
[80]). 
 Increased tumor associated macrophage (TAM) density 
is associated with tumor progression and metastasis (for 
review, see [81]). TAMs have many characteristics of an M2 
activation phenotype, and are thought to contribute to tumor 
development by releasing IL-10 and PGE2, which suppress 
the inflammatory reaction to the tumor [82]. TAMs also 
release pro-angiogenic factors such as vascular-endothelial 
growth factor (VEGF), endothelin 2 and plasminogen 
activator, and pro-proliferative factors such as epidermal 
growth factor (EGF), fibroblast growth factor, HGF, platelet-
derived growth factor, transforming growth factor " (TGF"), 
and IL-6 [83, 84]. TAMs are also thought to facilitate tumor 
cell invasion and metastasis by releasing MMP2 and MMP9, 
which modify the ECM and basement membrane, and by 
facilitating a paracrine loop of EGF and colony stimulating 
factor-1 signaling to promote metastasis [85]. Thus, TAMs 
endow tumors with an environment that enhances the 
survival, migration and proliferation of epithelial cells and 
are a large contributor to the observation that tumors are 
much like chronically unhealed wounds [86]. 
 Although there is insufficient evidence at this time to 
suggest that MSP/Ron-induced inflammation directly parti-
cipates in cancer progression, studies indicate that MSP is 
able to evoke dose-dependent superoxide anion production 
in human alveolar macrophages via src, MAPK, and p38 
signaling pathways [59]. In human alveolar macrophages 
from either smokers or non-smokers, MSP efficiently acti-
vates NF-kB. However, MSP evokes superoxide production, 
cytokine release and NFkB activation to significantly higher 
levels in cells from smokers versus those from non-smokers, 
indicating that MSP may enhance inflammation due to 
cigarette smoke [65]. Although this may contribute to 
tumorigenesis, there is another likely, and potentially more 
impactful, role for MSP/Ron in tumor progression and 
metastasis: polarization of TAMs to an M2 phenotype. 
CONSEQUENCES OF MSP/RON ACTIVATION IN 
TUMORS 
 As described above, pro-MSP is present in high con-
centrations in serum, and conversion of pro-MSP into MSP 
occurs locally at sites of inflammation [23]. A serine pro-
tease that was shown to cleave and activate MSP, matriptase, 
is normally present on macrophages, but is also upregulated 
in a large percentage of breast cancers [30]. In addition, 
RON is overexpressed to high levels (and Ron is phospho-
rylated) in ~50% of breast cancers [87]. It is reasonable to 
presume that activation of MSP locally, at sites of 
inflammation in tumors, would not only lead to activation of 
Ron on TAMs, but also on the tumor epithelium, where Ron 
has been shown to induce proliferation, survival, cell 
migration, EMT, invasion, and metastasis (see above). 
 Although the result of Ron signaling in TAMs is still 
unclear, MSP/Ron activates signaling pathways in macro-
phages that are known to be involved in tumor progression. 
Ron activation causes phosphorylation of the signal 
transducer and activator of transcription 3 (STAT3) protein 
[88], which is required for the immunosuppressive and 
tumor promoting effects of TAMs. In fact, STAT3 knockout 
mice [89] show similar inflammatory phenotypes as RON 
deficient mice, and several infectious agents are known to 
cause inflammation-induced cancer via STAT3 activation 
[90]. Furthermore, the MSP/Ron-induced cytokine IL-6 
activates STAT3 in both inflammatory cells and epithelial 
cells [90]. 
 In addition to the immunosuppressive effects of MSP/ 
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down-regulates STAT1 activity [27], which is involved in 
anti-tumor immune responses through upregulation of IL-12 
[90]. STAT1 and STAT3 clearly act in opposing roles with 
regard to immune responses against tumors; genetic deletion 
of STAT3 in immune cells leads to upregulated STAT1 
activity and increased anti-tumor properties [91]. Thus, it is 
likely that both STAT3 activation and STAT1 inhibition by 
MSP/Ron may manifest in immune tolerance to the tumor, in 
addition to the potential function of MSP/Ron in promoting 
secretion of pro-growth and pro-angiogenic factors by M2-
polarized TAMs. The potential consequences for MSP/Ron 
activation in tumors are summarized in Fig. (1). 
MSP/RON IN OSTEOLYTIC BONE METASTASIS 
 In addition to its expression and activity in macrophages, 
Ron is also expressed on osteoclasts, the specialized macro-
phages of bone. Ron becomes expressed on the surface of 
multinucleated osteoclast-like cells when human bone 
marrow cells are differentiated in vitro, and MSP activates 
osteoclasts, causing bone resorption [92]. In vivo, Ron is 
highly expressed on osteoclasts but does not appear to play a 
critical role in bone development, since mice lacking Ron 
function have no overt bone defects [56]. 
 The role of MSP in osteoclast activation is highly rele-
vant to breast cancer, since bone metastasis occurs in 70-
80% of patients and is therefore the most common site for 
relapse [93, 94]. Osteoclasts are activated in vitro by breast 
cancer cells that express MSP, and to a much greater extent 
than that induced by control tumors [38]. Furthermore, mice 
with mammary tumors expressing MSP spontaneously 
developed osteolysic bone metastasis, and breast cancer 
patients with high MSP/matriptase/Ron experienced signifi-
cantly more metastasis to bone than those without high 
MSP/matriptase/Ron [38]. A model for the role of MSP/Ron 
activity in osteolytic bone metastasis is shown in Fig. (2). A 
specific understanding of whether the MSP/Ron pathway 
contributes to the “vicious cycle” of breast tumor growth in 
bone that was previously proposed by Guise and Mundy (for 
recent reviews on breast cancer bone metastasis, see [93, 
95]), or whether MSP/Ron activation defines a new mecha-
nism for osteolysis remains to be determined. Understanding 
the role of the MSP/Ron pathway in breast cancer bone 
metastasis would have important clinical implications. 
MSP/RON AS A THERAPEUTIC TARGET 
 The ability to simultaneously block several key pathways 
that contribute to tumor progression might lead to more 
efficacious therapy. We suggest that the MSP/Ron pathway 
holds promising potential in this regard, since it is 
upregulated in a large proportion of cancers and contributes 
 
Fig. (1). Model for the contribution of MSP/Ron function in tumor progression and metastasis through both cell autonomous (tumor cell 
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to proliferation, survival, migration, and invasion of tumor 
cells. In addition, though, MSP/Ron activity also promotes 
M2 macrophage polarization, potentially leading to secretion 
of immunosuppressive cytokines as well as growth and 
angiogeneic factors that support the tumor. Blockade of 
MSP/Ron function might therefore interfere with critical 
tumor-promoting pathways in the tumor itself and in the 
tumor microenvironment. 
Strategies for Ron Inhibition 
 One can imagine several potential strategies to interfere 
with MSP/Ron function, including prevention of pro-MSP 
activation, blockade of MSP-Ron interaction and/or receptor 
dimerization, and inhibition of Ron kinase activity. Inhibi-
tion of MSP activating enzymes such as matriptase is 
unlikely to be effective due to redundancy between several 
serine proteases capable of activating MSP in vitro and in 
vivo [30, 31, 96]. Strategies to prevent ligand-receptor 
interactions and/or receptor downregulation could be 
achieved through generation of monoclonal antibodies 
(mABs). mABs can also have the added benefit of inducing 
antibody-mediated cellular cytotoxicity, analogous to that 
achieved by the HER2 antibody trastuzumab (Herceptin) in 
breast cancer. One Ron inhibitory antibody has been des-
cribed, and was shown to be effective in slowing growth of 
colon, lung, and pancreatic cancer xenografts [18]. 
 Inhibition of kinase activity may be less specific, due to 
high conservation of kinase domains within receptor tyrosine 
kinases, but would have the added benefit of oral availability 
and potentially lower cost. One advantage of targeting Ron 
with a small molecule kinase inhibitor is that Met kinase 
inhibitors are already available, some of which are being 
tested in clinical trials [34]. Since the kinase domains of Ron 
and Met are 68% identical, it is very likely that a Met 
inhibitor will also block Ron, at least to some extent. A dual 
Ron/Met inhibitor recently showed promising results in 
xenograft studies using Met-dependent cell lines or colon 
cancer cells expressing an endogenous, hyperactive form of 
Ron (see below) [55]. 
Challenges for Drug Development Against MSP/Ron 
 As with all potential new therapies, there are great 
challenges. The MSP/Ron pathway, in particular, may be 
even more confounding due to dual effects on the tumor and 
on the host immune system. One hurdle in drug development 
for oncology is pre-clinical testing in animal models, and 
immunodeficient mice are routinely used for initial studies. 
However, if MSP/Ron functions to promote tumor prog-
ression and/or metastasis through alteration of immune 
function, the results would be very difficult or impossible to 
discern in such a model. Use of syngenic, immunocompetent 
mouse models such as the one we developed [38] can 
overcome the problem of immune involvement, but pre-
 
Fig. (2). Model for the role of MSP/Ron activity in osteolytic bone metastasis as a complication of breast cancer. MSP can directly activation 
osteoclast activity through Ron stimulation. The ensuing bone resorption can release calcium and growth factors that stimulate tumor growth 
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cludes testing species-specific drugs such as anti-human Ron 
antibodies. Likewise, if activation of host macrophages is a 
key component of MSP/Ron function in tumors, drugs that 
recognize and inhibit both the human and murine Ron 
proteins would be required for validation in xenograft 
models.  
 The existence of multiple isoforms of Ron poses another 
challenge for drug development. There are a number of 
alternative Ron isoforms described. These include hyperac-
tive splice variants [97, 98], and an N-terminally truncated 
form of Ron, termed short form Ron (sfRon). sfRon is 
generated through utilization of a second, internal promoter 
within intron 10 of RON, creating a constitutively active 
form of the receptor that does not require ligand binding for 
activity [99]. sfRon is expressed in cell lines originating 
from multiple cancer types, and has been detected in primary 
breast cancers [99]. In mice, sfRon is required for transfor-
mation of erythroblasts by the Friend virus, and mice with a 
naturally occurring polymorphism in the sfRon promoter are 
resistant to this form of erythroleukemia [100]. Since the 
human sfRon promoter is relatively uncharacterized, it is 
unknown whether polymorphisms exist and are relevant to 
tumorigenesis. However, methylation of the main RON 
promoter may contribute to expression of sfRon in cancer 
cell lines [101]. Upregulation of active forms of Ron in 
cancer could serve as an important contributor toward 
resistance to therapies designed to interfere with ligand bind-
ing, for example. Thus, in our view, Ron kinase inhibitors 
may hold the greatest promise for targeted therapy against 
this pathway in breast cancer. 
RELEVANCE OF THE MSP/RON PATHWAY IN 
OTHER CANCERS 
 The Ron pathway may also be an excellent therapeutic 
target in cancers other than breast. Ron is overexpressed in a 
wide variety of human cancer tissues (Table 1) and, although 
its function in the epithelial compartment is not understood 
for all of these malignancies, the function of MSP/Ron in 
tumor inflammation is likely to be conserved. MSP and 
matriptase are also upregulated in many cancers [30, 38, 102, 
103], further supporting the idea that both autocrine and 
paracrine pathways could contribute to tumorigenesis and/or 
progression of malignancy. 
 Ron is overexpressed in small cell lung carcinoma 
(SCLC) cell lines, a pulmonary carcinoid cell line, and in 
non-small cell lung carcinoma (NSCLC) [102, 103]. While 
MSP expression is low to undetectable in both SCLC and 
pulmonary carcinomas, MSP is expressed in NSCLC pri-
mary tumors and cell lines [103, 104]. Addition of MSP to 
NSCLC cell lines expressing Ron resulted in increased cell 
motility [103]. In addition, overexpression of Ron in distal 
lung epithelial cells results in the development of lung 
adenomas in vivo [105]. 
 Expression of full length Ron, as well as various iso-
forms of Ron, has been demonstrated in human colon cancer 
cell lines as well as primary adenocarcinomas [97, 106, 107]. 
Ron is highly expressed in 60% of colorectal adenocarci-
nomas and its expression correlates with the degree of 
differentiation of these tissues [106, 107]. The constitutively 
active splice variants RON!155, RON!160, and RON!165 
are most notably expressed in colon cancers. Expression of 
RON!155 or RON!160 in NIH3T3 cells lead to tumor 
formation in vivo [97, 106-108], and expression of full 
length Ron in colon epithelial cells results in an increase in 
cell motility and invasiveness, while protecting the cells 
from apoptosis [108]. Silencing Ron expression by RNAi in 
colon cancer cell lines led to decreased cell proliferation and 
motility, with an increase in apoptosis [109]. Silencing of 
Ron also reduced tumorigenesis in vivo, suggesting that Ron 
expression is required to maintain the tumorigenic pheno-
types of colon cancer cells [109].  
Table 1. Expression of Ron in Primary Human Cancer Tissues 
 






! 50 (NSCLC# only)! [103]!








Liver! 29 (HCC† only)! [123]!
Gastric! 73! [18]!
Glioblastoma! 82! [121]!
* MSP/matriptase/Ron co-overexpression 
# Non small cell lung carcinoma 
† Hepatocellular carcinoma 
 
 While mutations in Ron have not been identified in 
cancers other than in a single lung tumor [110], two altera-
tions have been identified which may have a role in Crohn’s 
disease [111]. A genome wide linkage study performed with 
a cohort of Crohn’s disease patients identified strong linkage 
disequilibrium with two non-synonymous single nucleotide 
polymorphisms (SNPs) within the RON gene [111]. The first 
SNP, rs2230590, results in an Arg523Gln substitution while 
the second, rs1062633, results in a Gly1335Arg substitution. 
Further evidence for a role for the MSP/Ron pathway in 
inflammatory bowel diseases (IBD) comes from another 
genome wide linkage study performed on a cohort of IBD 
patients. This study identified significant linkage disequi-
librium with a SNP located within the MSP gene [112]. This 
nonsynonomous SNP, rs3197999, results in an Arg698Cys 
coding variant, which is predicted to interfere with the ability 
of MSP to bind to Ron [112]. Importantly, this coding 
variant showed association with both Crohn’s disease and 
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may have an important role in multiple forms of inflam-
matory bowel disease - though the mechanisms for this role 
have yet to be elucidated [112]. Associations between RON 
and MSP SNPs in inflammatory bowel diseases, which 
predispose patients to colon cancer (for a recent review, see 
[113]), provide further support for a connection between 
MSP/Ron function in inflammation and tumor progression 
(Fig. 1). 
 Ron is overexpressed in 79-93% of human pancreatic 
tissue samples, and in 83% of metastatic lesions [114, 115]. 
Activation of Ron by MSP in pancreatic cell lines leads to 
activation of Erk and Akt pathways, as well as induction of 
EMT characteristics such as increased cell migration, 
invasion, and loss of E-cadherin [114, 115]. Inhibition of 
Ron by a neutralizing antibody resulted in inhibition of the 
cell migratory and invasive phenotypes [115].  
 Ron is overexpressed in 33% of primary bladder tumors, 
where Ron levels correlated with poor grade as well as tumor 
size and stage [116]. Overexpression of Ron in a uroepi-
thelial cell line led to proliferation, motility, and increased 
survival [116]. Ron also cooperated with Met and EGFR in 
these cells; co-expression of Ron and Met was significantly 
associated with decreased survival and metastasis-free sur-
vival in 19% of patients [116]. Co-expression of Ron and 
EGFR was found in 33% of patients and significantly asso-
ciated with invasion, risk of recurrence, and decreased 
patient survival [117]. 
 Ron expression was detected in 56% of ovarian cancers 
and 60% of borderline ovarian tumors [118]. The level of 
Ron expression also significantly correlated with decreased 
survival in ovarian cancer patients [119]. A correlation 
between overexpression of Ron and concomitant expression 
of Met was demonstrated, and stimulation of ovarian cancer 
cell lines in vitro by MSP and/or HGF lead to increased 
motility and invasion [118, 120]. 
 Full length Ron, and several splice variants, were 
expressed in primary human glioblastomas and glioblastoma 
cell lines. Of the glioblastoma patient samples analyzed, 
82% expressed some form of Ron, while 100% of the glio-
blastoma cell lines analyzed demonstrated Ron expression 
[121]. MSP was also expressed in glioblastoma cell lines, 
where it functions to increase cell migration [121]. A novel 
splice variant, RON!90 was also identified, which inhibited 
MSP-induced phosphorylation of Ron as well as cell 
migration. 
 Ron was expressed in 92% of prostate tumor tissues and 
is overexpressed in prostate cancer cell lines [18]. Ron exp-
ression correlates with the stage of disease in the primary 
tumor and is expressed in prostate metastases. Levels of 
angiogenic chemokines correlate with Ron expression, and 
knockdown of Ron resulted in a decrease in angiogenic 
factors, NF-kB, and endothelial cell migration in vivo. 
Knockdown of Ron also resulted in decreased tumor growth 
and microvessel density, indicating that Ron may play an 
important role in the angiogenic process in prostate cancer 
[122]. 
 Ron has been shown to be overexpressed in two out of 
seven hepatocellular carcinoma (HCC) tissue samples. The 
cytokines IL-1", IL-6, and TNF" ! as well as the growth 
factor HGF were shown to increase Ron expression in a 
HCC cell line. These factors are commonly upregulated in 
liver disease and may therefore play a role in liver carci-
nogenesis through the upregulation of Ron [123]. Notably, 
the liver is the primary site of MSP production and therefore 
may contribute to increased Ron activity in the liver. 
CONCLUSIONS 
 In summary, the MSP/Ron pathway appears to be active 
in a large number of solid tumors from various organs, and 
MSP/Ron activity correlates with aggressive disease and 
poor outcome. The known roles for this pathway strongly 
suggest that MSP/Ron could play a significant, dual role in 
tumor progression by acting directly on tumor cells and 
indirectly through inflammatory cells. Thus, inhibition of 
Ron may provide a promising new avenue for cancer treat-
ment by simultaneously affecting at least two critical aspects 
of tumor progression. In breast cancer, blockade of Ron 
function may succeed in decreasing tumor growth, meta-
stasis, and destruction of bones through MSP-driven 
osteolysis. 
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 Inhibition of Ron Kinase 
Blocks Conversion of 
Micrometastases to Overt 
Metastases by Boosting 
Antitumor Immunity 
 Henok  Eyob 1 ,  Huseyin Atakan  Ekiz 1 ,  Yoko S.  DeRose 1 ,  
Susan E.  Waltz 3 ,  Matthew A.  Williams 2 , and  Alana L.  Welm 1 
 ABSTRACT  Many “nonmetastatic” cancers have spawned undetectable metastases before 
diagnosis. Eventual outgrowth of these microscopic lesions causes metastatic 
relapse and death, yet the events that dictate when and how micrometastases convert to overt metas-
tases are largely unknown. We report that macrophage-stimulating protein and its receptor, Ron, are 
key mediators in conversion of micrometastases to  bona fi de metastatic lesions through immune sup-
pression. Genetic deletion of Ron tyrosine kinase activity specifi cally in the host profoundly blocked 
metastasis. Our data show that loss of Ron function promotes an effective antitumor CD8 + T-cell 
response, which specifi cally inhibits outgrowth of seeded metastatic colonies. Treatment of mice with 
a Ron-selective kinase inhibitor prevented outgrowth of lung metastasis, even when administered 
after micrometastatic colonies had already been established. Our fi ndings indicate that Ron inhibitors 
may hold potential to specifi cally prevent outgrowth of micrometastases in patients with cancer in the 
adjuvant setting. 
 SIGNIFICANCE: Our data shed new light on an understudied, yet critically important aspect of metas-
tasis: the conversion of clinically undetectable micrometastatic tumor cells to overt metastases 
that eventually cause death of the patient. Our work shows that Ron inhibition can signifi cantly 
reduce metastatic outgrowth, even when administered after metastatic colonies are established. 
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 INTRODUCTION 
 Metastatic tumor growth in secondary organs is the main 
cause of death from cancer. For example, 20% to 30% of 
people diagnosed with stage II–III breast cancer eventually 
develop metastatic disease, which typically occurs 3 to 16 years 
after the initial diagnosis ( 1 ). This clinical “dormancy” period 
followed by late relapse is also frequently observed in cancers 
of the prostate, kidney, and thyroid, and in B-cell lymphomas 
and melanoma ( 2 ), making this a critical issue in clinical 
cancer biology. The long latency between excision of the pri-
mary tumor and development of clinically detectable distant 
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metastasis suggests that micrometastatic tumor cells are 
already seeded at other sites throughout the body at the time 
of diagnosis and surgery, but only “reawaken” after a period 
of inactivity or nonproductive growth. 
 The ability of micrometastatic tumor cells to convert into 
overt metastases is a key point in disease progression because, 
once detected, metastatic cancer is essentially incurable. Iden-
tifying pathways that can be targeted to prevent metastatic 
outgrowth is particularly important to understand from a 
therapeutic perspective, as prevention of very early tumor 
dissemination may not be clinically feasible. In fact, it has 
been suggested that “a new frontier” in cancer therapy will 
be to identify ways to revert or maintain cancers in an occult, 
minimal residual disease state ( 2, 3 ). 
 How tumor cells maintain and/or escape clinical dormancy 
is still largely unknown, but both tumor cell–intrinsic and
–extrinsic mechanisms seem to contribute. For example, 
occult cancer cells are often senescent or arrested in G 0 –G 1 
phase, a process that may be mediated by the T-helper cell 1 
cytokines IFN-γ and TNF-α ( 4 ). Failure to achieve suffi cient 
angiogenesis, even in a proliferating lesion, can also induce 
dormancy (for review, see ref.  5 ). Escape from immune-medi-
ated control has also been shown to contribute to outgrowth 
of micrometastases ( 6–8 ). A recent study of melanoma metas-
tasis showed that dissemination of cancer cells occurs early in 
tumorigenesis—even before tumors are detectable; however, 
their outgrowth in metastatic sites was limited by cytostatic 
CD8 + T lymphocytes ( 9 ). T lymphocytes have also been impli-
cated in late metastatic outgrowth in other models ( 6 ), and 
key cytokines that regulate T-cell activity can contribute to 
maintenance of the dormant state ( 8 ). However, the path-
ways by which micrometastatic tumor cells suppress T-cell 
responses to facilitate outgrowth and give rise to overt metas-
tases are very poorly understood. 
 CD8 + CTLs destroy tumor cells using perforin- and 
granzyme-mediated cell death ( 10 ) as well as by secreting 
TNF-α, causing tumor cell apoptosis ( 11, 12 ). To survive, 
tumor cells evade the immune system through mechanisms 
such as downregulation of class I MHC molecules, produc-
tion of anti-infl ammatory cytokines, and/or recruitment of 
infl ammatory-suppressor cells ( 13 ). However, most studies 
have focused on tumor–immune interactions in established 
primary tumors rather than in occult metastases. Identifying 
and targeting key mechanisms by which tumor cells medi-
ate suppression of CTLs during metastatic outgrowth holds 
potential as a strategy to reduce or prevent escape from dor-
mancy, and thereby block progression of metastasis. 
 Macrophage-stimulating protein ( MST1 ; gene product 
commonly referred to as MSP), one of its activating proteases 
( ST14 ; gene product commonly referred to as matriptase), 
and the MSP receptor Ron ( MST1R , gene product com-
monly referred to as Ron) become aberrantly overexpressed in 
around 40%, 45%, and 50% of human breast cancers, respec-
tively ( 14 ), and are upregulated in many other cancers as well 
( 15 ). We previously reported that overexpression of MSP/
matriptase/Ron is a strong, independent, poor prognostic 
factor for outcome in human patients with breast cancer due 
to metastasis, and that expression of MSP in a mouse model 
of mammary cancer was suffi cient to promote spontaneous 
metastasis to lung, lymphatics, and bone ( 14 ). However, the 
mechanisms by which MSP promotes metastasis were not 
understood. 
 MSP is constitutively secreted from the liver into serum 
as an inactive protein that is subsequently activated locally 
on macrophages by matriptase ( 16 ) or other extracellular 
serine proteases ( 17 ) in response to infection or injury. The 
processed MSP binds to Ron, which is selectively expressed 
on a subset of fully differentiated tissue macrophages, and 
also at low levels on various epithelial cells ( 18, 19 ). Ron is 
essential for protection from unregulated infl ammation in 
several models of infection or injury; MSP/Ron signaling is 
responsible for regulation of several infl ammatory media-
tors such as TNF-α, interleukin (IL)-12, IFN-γ, arginase, and 
inducible nitric oxide synthase ( 20–25 ). It is unknown, how-
ever, whether the role of MSP/Ron in infl ammation also 
contributes to its function in cancer metastasis. 
 Here, we used both genetic and pharmacologic approaches 
to interrogate the mechanism by which MSP drives metasta-
sis, and determined that MSP facilitates metastasis by sup-
pressing antitumor immunity. Blocking MSP/Ron signaling, 
specifi cally in the host, selectively prevents conversion of 
pulmonary micrometastases to metastatic colonies by elicit-
ing an effective CD8 + CTL response. We found that inhibi-
tion of Ron with a selective tyrosine kinase inhibitor reduced 
outgrowth of metastasis, even when treatment was delayed 
until after metastatic colonies were established. Thus, inhibi-
tion of MSP/Ron signaling holds promise as an exciting new 
therapeutic approach to managing the problem of metastatic 
outgrowth in the adjuvant setting. 
 RESULTS 
 Loss of Host Ron Signaling Blocks Metastasis 
 We previously described a highly metastatic transgenic 
mouse model of breast cancer in which MSP expression drives 
widespread spontaneous metastasis to clinically relevant sites 
( 14 ). MSP is a secreted protein, and both the tumor cells and 
host tissues express endogenous Ron, so the prometastatic 
function of MSP could be attributed to direct effects on tumor 
cells or to indirect effects on the host tumor microenvironment. 
To determine whether MSP/Ron promotes metastasis through 
cell-autonomous or non-cell–autonomous mechanisms, we 
transplanted polyomavirus middle T antigen (PyMT)-MSP 
tumor cells or PyMT–MSCV-IRES-GFP (MIG) control tumor 
cells into cleared mammary fat pads of immune-competent 
syngeneic wild-type (WT) mice or syngeneic mice lacking Ron 
activity through targeted deletion of the intracellular kinase 
domain ( Ron TK−/−  ; ref.  21 ;  Fig. 1A ). We found that knocking 
out host Ron function had no signifi cant effect on primary 
tumor development, growth rates, proliferation, or apoptosis 
( Table 1 and Supplementary Fig. S1A and S1B). However, 
loss of host Ron activity nearly eliminated spontaneous lung 
metastasis ( P < 0.0001;  Table 1 ;  Fig. 1B ), suggesting that MSP/
Ron functions through the host to promote metastasis. We 
also noted that, although not statistically signifi cant, control 
PyMT-MIG tumors were also less metastatic in the  Ron TK −/− 
hosts, suggesting that host Ron may promote metastasis even 
in the absence of overexpressed MSP from the tumor (Sup-
plementary Table S1). In fact, MSP is constitutively produced 
by hepatocytes and present in the serum, where it can then 
on July 20, 2013. © 2013 American Association for Cancer Research. cancerdiscovery.aacrjournals.org Downloaded from 
Published OnlineFirst April 23, 2013; DOI: 10.1158/2159-8290.CD-12-0480 
  
74 
 JULY  2013!CANCER DISCOVERY | 753 
Inhibition of Ron Kinase Blocks Metastatic Outgrowth RESEARCH BRIEF
 Figure 1.   Loss of host Ron signaling attenuates metastasis specifi cally during the conversion of seeded micrometastasis to overt metastasis. A, schematic 
of the experimental strategy to determine whether host MSP/Ron signaling plays a role in mammary tumor development, initiation, and/or metastasis. B, repre-
sentative image of spontaneous metastasis in lung sections from tumor-bearing WT and  Ron TK −/− hosts. C, PyMT mRNA expression from peripheral blood (nor-
malized to glyceraldehyde-3-phosphate dehydrogenase) as a surrogate marker for circulating tumor cells in WT and  Ron TK −/− mice ( n = 6 and 5, respectively). 
D, quantifi cation of tumor-cell seeding in the lung 36 hours after intravenous injection into WT or  Ron TK −/− hosts ( n = 3/group). E, quantifi cation of the meta-
static tumor burden in the lung per fi eld of vision 96 hours following intravenous tumor cell injection into WT or Ron TK −/− hosts ( n = 4/group). F, quantifi cation of 
metastatic tumor burden in the lung per fi eld of vision 10 days following intravenous tumor cell injection into WT or  Ron TK −/− hosts ( n = 5 and 4, respectively).
G, quantifi cation of DiI-labeled tumor cells in the lung 10 days following intravenous injection of LAP-MSP (lung alveolar/bronchiolar carcinoma-P0297) lung 
cancer into WT or  Ron TK −/− hosts ( n = 5). Data are depicted as mean ± SEM. *,  P < 0.05 (unpaired, two-sided  t test). MMTV, mouse mammary tumor virus; N.S., not 



























































































































PyMT-MSP 10 d LAP-MSP 10 d
Ron TK –/– host
Transduce tumor cells





















































 Table 1.   Summary of the effect of host Ron on PyMT-MSP tumor growth, spontaneous 








Survival (days to 
ethical endpoint) c 
FVB WT ( n = 15) 35 66 13/15 (87%) 40
FVB  Ron TK −/− ( n = 15) 35 53 1/15 (6.7%) a 52 d 
FVB  Ron TK −/− ; Prkdc scid 
( n = 7)
41 71 5/7 (71.4%) b ND e 
 a P < 0.0001 vs. WT (Fisher exact test). 
b P < 0.005 vs. FVB  Ron TK −/− (Fisher exact test).
cExperimental metastasis assay; mice were euthanized when in respiratory distress.
 d P < 0.05 (Mantel–Cox test).
 e Not done. 
be activated by macrophages in response to tissue injury or 
remodeling ( 26, 27 ). 
 Metastasis involves multiple steps: cell detachment from 
the primary tumor mass, local tissue invasion, entry into the 
circulation, extravasation into new tissues, colonization, and 
growth at the distant site ( 28 ). To test whether lack of metas-
tasis in the  Ron TK −/− hosts was due to a defect in invasion or 
intravasation, we analyzed the relative numbers of circulating 
tumor cells (CTC) in both groups of mice. CTCs were meas-
ured in blood from tumor-bearing WT and  Ron TK −/− mice 
by quantifying levels of tumor-specifi c  PyMT mRNA as a sur-
rogate measure. Evidence for CTCs was found in both groups 
of mice, but we detected no signifi cant difference between WT 
and  Ron TK −/− tumor-bearing hosts ( Fig. 1C ). To determine 
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whether host Ron plays a role in the later steps of metas-
tasis, such as metastatic cell extravasation, seeding, and/or 
colonization of lungs, we conducted experimental metastasis 
assays. We injected equal numbers of identical tumor cells 
into the tail veins of WT or  Ron TK −/− mice, and examined 
the ability of the cells to extravasate and seed the lung (36 
hours later) and the ability of the cells to form colonies (5 
days later; time points are based on ref.  29 ). Tumor burden 
was calculated using two different methods, which both con-
sistently supported the same conclusions (see Methods for 
details). Both WT and  Ron TK −/− hosts were equally competent 
for extravasation and metastatic seeding ( Fig. 1D ). However, 
 Ron TK −/− hosts were defective in supporting the conversion 
of the seeded micrometastatic cells into metastatic colonies, 
resulting in less tumor burden in the lungs 5 days after injec-
tion ( Fig. 1E and Supplementary Fig. S1C). This effect was 
sustained; tumor burden in the lungs was still signifi cantly 
reduced 10 days after injection ( Fig. 1F and Supplementary 
Fig. S1D), and  Ron TK −/− hosts were able to survive about 
50% longer than WT hosts before reaching the experimental 
endpoint of respiratory distress ( Table 1 ). Similar results were 
obtained using syngeneic mouse lung cancer cells (LAP-MSP; 
ref.  30 ;  Fig. 1G ), as well as with PyMT-MIG control mammary 
tumor and LAP-MIG control lung tumor cells (Supplemen-
tary Fig. S2A and S2B). Thus, host Ron activity specifi cally 
facilitates the transition from micrometastasis to overt metas-
tasis in multiple models of metastasis. 
 Ron TK −/− Hosts Mount a Robust CTL 
Response to Tumors, Which Is Critical 
for Preventing Metastasis 
 The expression pattern and known function of Ron ( 15 ) led 
us to postulate that the Ron-dependent host role in metastasis 
would be related to immune function. We fi rst assessed splenic 
leukocyte populations in tumor-bearing WT or  Ron TK −/− mice. 
We observed no signifi cant differences between cohorts with 
respect to the proportion of splenic CD11b + macrophages, 
Gr-1 + granulocytes, CD11b + /Gr-1 + myeloid-derived suppressor 
cells, CD11c + dendritic cells, CD4 + T cells, or CD4 + CD25 + T 
cells (Supplementary Fig. S3A–S3F). However, we detected a 
signifi cant (∼twofold) increase in the proportion of splenic 
CD8 + T cells in  Ron TK −/− mice compared with WT hosts ( Fig. 
2A ). Large clusters of CD8 + T cells were also detected around 
the margin of primary tumors in  Ron TK −/− hosts compared 
with a general lack of CD8 + T cells around tumors in WT hosts 
( Fig. 2B ). We could not detect CD8 + T cells within the core of 
the primary tumor in either group of mice (data not shown). 
WT and  Ron TK −/− mice without tumors had similar numbers 
and proportions of splenic CD8 + T-cell populations ( Fig. 2A , 
naïve hosts), indicating that the expansion of CD8 + T cells in 
 Ron TK −/− hosts is tumor-dependent. 
 To specifi cally determine whether CD8 + T cells respond to 
the tumor challenge in the context of an experimental metas-
tasis assay, we analyzed the immune milieu in the  Ron TK −/− 
hosts and WT hosts in more detail. The initial stages of T-cell 
activation involve expansion of CD8 + T cells in response to 
antigen stimulation ( 31 ), so we postulated that an expan-
sion of CD8 + T cells in the spleen or peripheral blood 
would precede an antitumor cytotoxic response in the lungs, 
which occurs between 36 and 96 hours after tumor injection 
( Fig. 1D and E ). Therefore, we analyzed the CD8 + T-cell 
response at an intermediate time point (72 hours after tumor 
injection).  Ron TK −/− hosts had an expanded CD8 + T-cell pool 
in the peripheral blood relative to WT hosts, in both the 
mammary and lung cancer models ( Fig. 2C and D ). Again, 
nontumor-bearing  Ron TK −/− and WT mice had similar levels 
of CD8 + T cells in the blood ( Fig. 2C , naïve hosts). 
 Despite increased expansion of CD8 + T cells in the periphery 
of  Ron TK −/− mice 72 hours following tumor injection, we did 
not observe differences in the overall proportion of CD8 + T 
cells infi ltrating the lungs at this time point (data not shown). 
To determine whether the CD8 + T cells were active, we profi led 
the infl ammatory cytokines produced by CD8 + T cells isolated 
from both the lungs and peripheral blood of tumor-bearing 
animals. We found that the CD8 + T cells in the lungs of  Ron 
TK −/− hosts produced more TNF-α than those from WT hosts 
( Fig. 2E ), suggesting a stronger proinfl ammatory immune 
milieu in the lungs of  Ron TK −/− hosts specifi cally following 
tumor challenge. CD8 + T cells from nontumor-bearing WT 
and  Ron TK −/− hosts had similar low levels of TNF-α ( Fig. 2E , 
naïve hosts). TNF-α is a potent antitumor factor secreted by 
immune cells that induces tumor cell apoptosis ( 12 ), and 
canonical MSP/Ron signaling is known to downregulate IL-12 
and TNF-α to drive the switch from classical to alternative 
macrophage activation ( 20 ,  22 ,  23 ). Consistent with this, mac-
rophages derived from lungs of  Ron TK −/− mice 72 hours 
after tumor injection expressed increased IL-12 compared with 
macrophages isolated from WT hosts at the same time point 
( Fig. 2F and Supplementary Fig. S4). Moreover, macrophages 
from the spleen of  Ron TK −/− hosts also expressed more TNF-α 
( Fig. 2G and Supplementary Fig. S4). Macrophages from non-
tumor-bearing WT and  Ron TK −/− hosts had similar, low levels 
of IL-12 ( Fig. 2F , naïve hosts) and TNF-α ( Fig. 2G , naïve hosts). 
Thus, loss of host Ron activity enhanced tumor-dependent 
production of proinfl ammatory cytokines by macrophages, 
allowed expansion of the peripheral CD8 + T-cell population, 
and promoted infi ltration of TNF-α–producing CD8 + T cells 
into the lungs 72 hours following tumor challenge. These 
events preceded the diminished tumor burden in the lungs of 
 Ron TK −/− hosts (at the 96-hour time point;  Fig. 1E ), suggest-
ing that enhanced antitumor immunity could be the cause of 
reduced metastasis in  Ron TK −/− mice. 
 To test whether the improved CD8 + T-cell response in  Ron 
TK −/− hosts was directly related to inhibition of metastasis, 
we asked if loss of T cells would restore metastasis in  Ron 
TK −/− hosts. We crossed  Ron TK −/− mice with  Prkdc scid mice, 
which lack functional lymphocytes. The double mutants, 
versus control  Ron TK +/+ ; Prkdc scid littermates (all backcrossed 
to the FVB background), were used as hosts for orthotopi-
cally transplanted PyMT-MSP tumors. Tumors developed 
and grew with similar rates in both hosts; however,  Ron 
TK −/− ; Prkdc scid hosts displayed normal (restored) metastasis 
compared with the almost complete lack of metastasis in 
immune-competent  Ron TK −/− hosts ( Table 1 ;  P = 0.0043). 
 To specifi cally determine whether CD8 + T cells were 
required to inhibit metastasis in  Ron TK −/− hosts, we selec-
tively depleted CD8 + T cells using anti-CD8 antibodies in 
the context of a 10-day lung colonization assay (as in  Fig. 
1F ). Successful depletion of CD8 + T cells was confi rmed by 
fl ow cytometry on splenic, lung, and peripheral blood cell 
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populations (Supplementary Fig. S5A–S5C). Depletion of 
CD8 + T cells resulted in a signifi cant, approximately twofold 
increase in metastatic tumor burden in the lungs of  Ron TK −/− 
mice ( Fig. 3A and Supplementary Fig. S5D). 
 We next sought to determine if the tumor-induced expan-
sion of CD8 + T cells also resulted in increased cytotoxic 
ability. We isolated CD8 + T cells from the blood of  Ron TK −/− 
and WT hosts 96 hours following intravenous injection of 
PyMT-MSP tumor cells. We cocultured PyMT-MSP tumor 
cells with CD8 + T cells (1:1 ratio) for 24 hours. We observed 
that CD8 + T cells isolated from the blood of  Ron TK −/− hosts 
had increased cytotoxic ability  in vitro , as evidenced by the 
increased proportion of Annexin V + propidium iodide (PI) + 
double-positive tumor cells ( Fig. 3B ). This was tumor specifi c; 
CD8 + T cells isolated from naïve WT and  Ron TK −/− hosts had 
similar, low levels of cytotoxicity ( Fig. 3B , naïve hosts). 
 We next wanted to determine whether CD8 + T cells were 
suffi cient to block metastasis in tumor-bearing  Ron TK −/− 
hosts  in vivo . We isolated tumor-educated CD8 + T cells from 
the spleens of tumor-bearing mice and conducted adop-
tive transfer of these cells into tumor-naïve, syngeneic  Ron 
TK +/+ ; Prkdc scid mice, which lack endogenous lymphocyte func-
tion. One day later, we injected the tumor cells (derived from 
the same donor mice as the CD8 + T cells) into the tail veins 
( Fig. 3C ). This strategy allowed us to determine if the CD8 + 
T cells that were educated and activated in tumor-bearing 
WT or  Ron TK −/− mice were suffi cient to affect metastasis in 
a naïve host in the absence of other functional lymphocytes. 
Adoptive transfer of CD8 + T cells from WT tumor-bearing 
mice did not have a signifi cant effect on metastasis, whereas 
adoptive transfer of the same number of CD8 + T cells from 
tumor-bearing  Ron TK −/− mice signifi cantly reduced meta-
static tumor burden in the lungs ( Fig. 3D and Supplementary 
Fig. S5E). Collectively, these results showed that the expanded 
CD8 + T-cell population in tumor-bearing  Ron TK −/− mice was 
both necessary and suffi cient to reduce metastasis, whereas 
 Figure 2.   Loss of host Ron signaling results in expansion of CD8 + T cells and promotes production of proinfl ammatory cytokines. A, representative 
fl ow-cytometric analysis (left) and graph (right) depicting the population of CD8 + T cells in spleens of tumor-bearing WT and  Ron TK −/− mice ( n = 6 and 7, 
respectively), as well as naïve hosts. B, representative immunohistochemical analysis of CD8 + T-cell infi ltration into the primary tumors of WT (left) and 
 Ron TK −/− hosts (right). The dashed lines denote the tumor–stroma border. C, representative fl ow-cytometric analysis (left) and graph (right) depicting 
the population of CD8 + T cells in the blood of tumor-bearing WT and  Ron TK −/− mice 72 hours after PyMT-MSP tumor cell injection ( n = 5/group) as well as 
naïve hosts. D, Representative fl ow-cytometric analysis (left) and graph (right) showing the proportion of CD8 + T cells in the blood of tumor-bearing WT 
and Ron TK −/− mice 72 hours after LAP-MSP injection ( n = 5/group). E, representative fl ow-cytometric analysis (left) and graph (right) depicting the popu-
lation of TNF-α–expressing CD8 + T cells in the lungs of tumor-bearing WT and  Ron TK −/− mice 72 hours after PyMT-MSP tumor cell injection ( n = 5/group) 
as well as naïve hosts. F, graph depicting the population of IL-12–expressing CD11b + cells in the lungs of tumor-bearing WT and  Ron TK −/− hosts 72 hours 
after PyMT-MSP tumor cell injection ( n = 5/group) as well as naïve hosts ( n = 4). G, graph depicting the population of TNF-α–expressing CD11b + cells in 
the spleen of tumor-bearing WT and  Ron TK −/− hosts 72 hours after PyMT-MSP tumor cell injection ( n = 5/group) as well as naïve hosts ( n = 4). Data are 
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the CD8 + T cells in tumor-bearing WT mice were incapable of 
antimetastatic activity. Our data shed light on how MSP/Ron 
signaling causes metastasis of breast cancer, at least in these 
animal models: through suppression of an effective antitu-
mor CD8 + T-cell response. Blocking host Ron activity relieved 
this immunosuppression and effectively inhibited metastasis. 
Our next question centered on the potential clinical relevance 
of our fi ndings. 
 Pharmacologic Inhibition of Ron Diminishes 
Metastatic Outgrowth 
 To test whether pharmacologic inhibition of Ron could 
decrease metastatic outgrowth in WT mice, we used BMS-
777607/ASLAN002, a small-molecule inhibitor selective for 
Ron and, to a lesser extent, its homolog Met ( 32 ). We validated 
the ability of BMS-777607/ASLAN002 to inhibit mouse Ron 
activity by treating PyMT tumor cells, which express endog-
enous Ron, with MSP in the presence or absence of BMS-
777607/ASLAN002. As expected from published data ( 32 ), 
this compound was effective in diminishing MSP-induced 
phosphorylation of Ron at submicromolar concentrations 
(IC 50 < 500 nmol/L ; Supplementary Fig. S6A). 
 To establish whether BMS-777607/ASLAN002 treatment 
could reduce metastatic colonization in a manner comparable 
with that seen in  Ron TK −/− hosts, we fi rst tested Ron inhibi-
tion in the prophylactic setting. WT mice were treated orally 
with 50 mg/kg BMS-777607/ASLAN002 (or vehicle control) 
once a day for 2 weeks (days 1–14). PyMT-MSP tumor cells 
were injected into the tail vein on day 3, and on day 14 the 
lungs were harvested and assessed for tumor colonization. The 
results showed that prophylactic treatment with BMS-777607/
ASLAN002 signifi cantly reduced metastatic outgrowth in the 
lungs by two- to threefold ( Fig. 4A and Supplementary Fig. 
S6B). To determine if CD8 + T cells mediated the anticoloniza-
tion effects of BMS-777607/ASLAN002, WT mice were treated 
orally with 50 mg/kg BMS-777607/ASLAN002 (or vehicle con-
trol) once a day for 7 days. We concurrently depleted CD8 + T 
cells with anti-CD8 antibodies. PyMT-MSP tumor cells were 
injected into the tail vein on day 3, and 96 hours later the 
lungs were harvested and assessed for tumor colonization. 
Treatment with BMS-777607/ASLAN002 resulted in two- to 
threefold more TNF-α–positive macrophages, similar to the 
increased proinfl ammatory milieu we had observed in  Ron 
TK −/− mice ( Fig. 4B and Supplementary Fig. S6C). However, 
treatment with BMS-777607/ASLAN002 in the absence of 
CD8 + T cells did not reduce tumor colonization, indicating 
that CD8 + T cells are key mediators of the anticolonization 
effect of BMS-777607/ASLAN002, phenocopying the genetic 
loss of Ron ( Fig. 4C and Supplementary Fig. S6D). 
 To mirror the clinical situation more closely, however, 
where micrometastases may have been seeded before diagno-
sis, we next tested Ron inhibition in the “adjuvant” setting. 
We injected PyMT-MSP tumor cells into the tail veins of WT 
mice and waited 14 days for metastatic colonies to become 
fully established, then began daily treatment for 8 days (days 
14–22). On day 22, the lungs were harvested and assessed for 
metastatic outgrowth by determining the percentage of lung 
area that was taken by tumor. Treatment with BMS-777607/
ASLAN002 attenuated the formation of metastatic nodules 
by approximately fourfold, even when administered after 
metastatic colonization had occurred ( Fig. 4D and E ). Thus, 
inhibition of Ron kinase activity carries promising potential 
as a novel therapeutic option to inhibit metastatic outgrowth 
when given in the adjuvant setting. 
 Figure 3.   The CD8 + cytotoxic T-cell response in  Ron TK −/− hosts in 
response to tumors is necessary and suffi cient to block metastasis. 
A, quantifi cation of the tumor burden in the lungs 10 days following 
intravenous tumor cell injection in animals treated with anti-CD8 anti-
body or immunoglobulin G (IgG) control ( n = 5/group). B, representative 
fl ow-cytometric analysis (left) and graph (right) depicting tumor cell 
apoptosis 24 hours following coculture of PyMT-MSP tumor cells and 
CD8 + T cells isolated from the blood of tumor-bearing WT and  Ron 
TK −/− hosts ( n = 3/group) and naïve hosts ( n = 3/group). C, schematic of 
the experimental strategy to determine whether tumor-educated CD8 + 
T cells from  Ron TK −/− mice were suffi cient to inhibit metastatic lung 
colonization. D, quantifi cation of the metastatic tumor burden in mice 
10 days following intravenous injection of tumor cells (11 days following 
T-cell adoptive transfer;  n = 4 for adoptive transfer of CD8 + T cells from 
WT or  Ron TK −/− mice, and  n = 10 for controls receiving no T cells). Data 
are depicted as mean ± SEM. *,  P < 0.05; **,  P < 0.005 (unpaired, two-
sided  t test). N.S., not statistically signifi cant. 
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 Figure 4.   Treatment with a Ron inhibitor signifi cantly reduces meta-
static outgrowth. A, quantifi cation of the metastatic tumor burden 
in the lungs of mice treated prophylactically with vehicle only versus 
50 mg/kg BMS-777607/ASLAN002 ( n = 6/group). B, quantifi cation 
of the population of TNF-α–expressing CD11b + cells in the lungs of 
tumor-bearing WT and  Ron TK −/− hosts treated with vehicle only versus 
50 mg/kg BMS-777607/ASLAN002 96 hours after PyMT-MSP tumor 
cell injection ( n = 4 and 3, respectively) and naïve hosts ( n = 4). C, quan-
tifi cation of labeled tumor cells 96 hours after intravenous tumor cell 
injection in animals treated with vehicle or BMS-777607/ASLAN002 
following depletion with an anti-CD8 antibody or immunoglobulin G 
(IgG) control ( n = 4, 3, 3, and 4, respectively). D, representative hema-
toxylin and eosin staining of metastatic growth in the lungs of WT mice 
treated with vehicle only or 50 mg/kg BMS-777607/ASLAN002 (top 
pictures represent least metastasis observed in each group and bot-
tom pictures represent most metastasis observed in each group). 
E, percentage of lung area occupied by metastatic growth in the lungs 
of mice treated with vehicle only ( n = 3) versus 50 mg/kg BMS-777607/
ASLAN002 ( n = 4). Data are depicted as mean ± SEM. *,  P < 0.05; **,
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 Ultimately, our ability to reduce cancer mortality depends 
on identifying ways to prevent or treat distant metastatic dis-
ease over long periods of time. The data presented here reveal 
that the Ron ligand, MSP, which is aberrantly overexpressed 
in 40% of human breast cancers and many other cancers 
( 14, 15 ), promotes metastasis by inhibiting an effective anti-
tumor immune response through activation of Ron signaling 
in the host. Although there are clearly many ways that tumors 
achieve metastasis, we propose that some tumors upregulate 
MSP as one way to effectively evade the immune system. Fur-
thermore, our data show that host Ron is also important for 
immune suppression when tumors themselves do not over-
express MSP, presumably through activation of endogenous 
serum-derived MSP by macrophage- and/or tumor-derived 
serine proteases ( 16 ). Together, our data suggest that block-
ing Ron kinase activity allows for reactivation of the antitu-
mor immune response and reduces metastatic outgrowth. 
 It has long been known that infi ltration of CD8 + CTLs into 
tumors is a useful prognostic indicator for various types of 
tumors ( 33–35 ). Recent evidence suggests that immunosur-
veillance by CD8 + T cells keeps melanoma metastasis in check 
by promoting tumor dormancy ( 9 ). However, suppression of 
the immune system, also known as immunosubversion, is a 
critical step in tumor development ( 36 ). Tumors downregulate 
MHC molecules and overproduce arginase-1 and indoleamine 
2,3-dioxygenase , both of which inhibit CD8 + T-cell function. 
Hypoxia also suppresses T-cell activity through expression of 
hypoxia-inducible factor in macrophages ( 36 ). These effects 
likely cooperate, ultimately leading to a strong immuno-
suppressive environment in tumors. Such redundancy may 
explain why primary tumor growth is similar in WT and  Ron 
TK −/− mice despite increased CD8 + T-cell infi ltration around 
the periphery of primary tumors in  Ron TK −/− hosts. Con-
versely, tumor cells that have seeded a new environment or 
are just beginning to effectively colonize the distant organ 
may be more vulnerable to immune-mediated control. Indeed, 
our results show that cells that are in the process of convert-
ing from seeded tumor cells to overt metastases are vulner-
able to CD8 + T cells. Here, we describe a novel pathway that, 
when inhibited, is suffi cient to activate the CTL response, 
reducing metastasis and extending life—at least in immune-
competent mouse models. These results warrant additional 
studies focused on whether Ron inhibitors could be tested for 
antimetastatic effects in the clinical adjuvant setting. 
 The precise molecular role for MSP/Ron in suppressing 
antitumor immunity is still unknown and will be the focus of 
important future studies. Tumors are sites of chronic infl am-
mation and are reminiscent of unhealed wounds, where 
tumor-associated macrophages (TAM) seem to be skewed 
toward an M2 alternative activation state ( 37, 38 ). Although 
M2 macrophages are important for wound healing, they are 
thought to contribute inadvertent advantages to tumors by 
stimulating angiogenesis and producing polyamines, growth 
factors, and cytokines that favor tumor growth. Several fac-
tors, most notably colony-simulating factor 1, have been 
implicated in the recruitment of macrophages into tumors 
where they promote metastasis ( 39, 40 ), but little is known 
about the specifi c signaling pathways in tumors that drive the 
M2 state of TAMs. On the basis of published studies and our 
results, it is tempting to speculate that MSP/Ron signaling 
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simply favors conversion of TAMs to an M2 state, resulting in 
suppression of CTL responses ( 41 ). In support of this hypoth-
esis, subcutaneous growth of several mouse tumor types is 
regulated extrinsically through Ron function in TAMs, which 
affects CTL responses ( 25 ,  42 ). In addition, Ron-defi cient 
mice clearly exhibit amplifi ed infl ammatory responses upon 
challenge with infection or injury due to unregulated pro-
duction of proinfl ammatory cytokines ( 21 ,  43 ,  44 ). A similar 
mechanism could be involved in the tumor setting, whereby 
increased production of IL-12 and TNF-α from  Ron TK −/− 
macrophages is either causal to or symptomatic of a broad 
proinfl ammatory cytokine milieu that results in improved 
CD8 + T-cell responses, including production of TNF-α. How-
ever, the immune milieu of tumors (and the resulting effects 
on tumor progression) is extremely complicated; detailed 
genetic and immunologic studies will be required to deter-
mine the precise role of Ron in antitumor immunity. 
 Cancer immunotherapy carries strong appeal because the 
immune response is individualized, it is effective against 
diverse antigens, and it is potentially able to evolve and retain 
immunologic memory for long-term control of disease. A 
major challenge, however, is that by the time tumors are clini-
cally detectable they are already “invisible” to the immune 
system. Strong natural selection exists to favor tumor cells 
that can escape immune control by promoting immune 
tolerance and/or by fostering a strong immunosuppressive 
environment that renders effector cells inactive ( 45 ). These 
same issues have also been barriers to effective antitumor 
immune therapies, and the clinical results of immunotherapy 
for breast cancer have been, at most, only moderately effective 
( 46 ). Drugs that block the inhibitory signals on T cells, such 
as CTLA-4 inhibitors, are now being used in combination 
with immunotherapy to generate a more productive antitu-
mor immune response ( 47 ). Future work will be important to 
determine whether Ron inhibitors may function in a similar 
immune-modulatory role to boost the clinical response to 
immunotherapy and whether CTL activity is a good clinical 
biomarker of Ron inhibition. 
 METHODS 
 Mice and Cells 
 All procedures were reviewed and approved by the University of 
Utah Institutional Animal Care and Use Committee. FVB mice with 
a deletion in the Ron tyrosine kinase domain (TK −/− ) have been 
described previously ( 21 ).  Prkdc scid mice (The Jackson Laboratory) and 
 Ron TK −/− or WT mice were backcrossed to generate  Ron TK −/− ; Prkdc scid 
mice and  Ron TK +/+ ; Prkdc scid mice on the FVB background. Tumors 
were generated from mouse mammary tumor virus (MMTV)-PyMT 
transgenic mice engineered to express MSP-IRES-GFP or IRES-GFP 
(pMIG), and 100,000 GFP + cells were orthotopically transplanted as 
described previously ( 14 ). LAP-0297 lung cancer cells ( 30 ) were engi-
neered to express MSP-IRES-GFP (LAP-MSP) using the same method, 
and 250,000 cells were injected into the tail vein. These cells were 
obtained from Dr. Peigen Huang (Harvard/Massachusetts General 
Hospital, Boston, MA) without additional authentication. 
 Immunohistochemistry 
 Tissues were processed, sectioned (5 µm), and stained using stand-
ard procedures. Apoptosis was assessed with terminal deoxynucle-
otidyl transferase–mediated dUTP nick end labeling assays (Roche). 
Antibodies used for immunohistochemistry were phosphohistone 
H3 (1:100; Cell Signaling Technology) and CD8 (1:100; Abcam). The 
Envision+System HRP Detection Kit (DAKO) and Vector M.O.M. 
and horseradish peroxidase (HRP) kits were used according to manu-
facturers’ instructions. 
 Lymphocyte Isolation and FACS 
 Splenocytes were isolated by disrupting spleens over a wire mesh, 
followed by red blood cell (RBC) lysis. Lung lymphocytes were 
isolated following digestion of lungs in Collagenase IV (Sigma) for 
1 hour, followed by Percol (Sigma) separation. Peripheral blood 
lymphocytes were isolated as previously described ( 48 ). Briefl y, blood 
was harvested from WT and  Ron TK −/− mice into anticoagulant citrate 
dextrose solution Formula A followed by incubation with dextran 
solution for 20 minutes at 37°C. The upper layer of RBC-depleted 
fl uid was harvested, and lymphocytes were collected. Antibodies 
used for fl uorescence-activated cell sorting (FACS) were CD8α-FITC, 
CD8β-PE, CD4-FITC, CD45-FITC, CD11c-PeCy7, CD11b-PeCy7, Gr-
1-APC, CD25-PE (all 1:400; BD Pharmingen) for cell surface stain-
ing. Intracellular FACS staining was done with TNF-α-APC and 
IL-12-eFluor450 (1:400; eBioscience). For cell surface staining, cells 
were incubated in 2% FBS in PBS for 20 minutes. For intracellular 
staining, cells were stimulated for 6 hours with phorbol 12-myristate 
13-acetate/ionomycin in the presence of Brefeldin A (1 µL/mL). Cells 
were stained with cell surface staining antibodies, permeabilized, 
and stained with anticytokine antibodies as per manufacturer’s 
instructions (BD Biosciences). Cells were analyzed using FACScan 
and FACS Canto II cytometers (BD Biosciences) and results analyzed 
using FlowJo Software (Treestar). 
 Experimental Metastasis Assays 
 Tumor cells were stained with DiI (Invitrogen) and resuspended 
in Hank’s Balanced Salt Solution at 10 6 cells/mL, and  250 µL 
(250,000 cells) was injected into the lateral tail veins of  Ron TK −/− 
or WT mice. At experimental endpoints, mice were euthanized, 
and lungs were prepared by perfusion with 4% paraformaldehyde 
and frozen in optimum cutting temperature compound. Images of 
16-µm sections were captured using ×10 magnifi cation. Fluorescent 
cells/colonies were quantifi ed using ImageJ software. Tumor burden 
was calculated by multiplying the colony count by the colony size 
for each section. Alternatively, as a secondary quantitative measure, 
epithelial cells from freshly harvested lungs were collected following 
Percol (Sigma) separation and analyzed with a FACSCanto II cytom-
eter to calculate percentage of DiI-labeled tumor cells. 
 CD8 +  Killing Assays 
 CD8 + T cells were magnetically sorted from the blood of WT and 
Ron TK −/− hosts 96 hours after intravenous injection of PyMT-MSP 
tumor cells and control nontumor-bearing hosts (CD8α microbeads; 
MACS). Subsequently, the 50,000 CD8 + T cells were cultured with 
plate-bound anti-CD3 antibody (BD; 5 µg/mL) and cocultured with 
50,000 PyMT-MSP tumor cells ( 12 ,  49 ). Twenty-four hours later, cell 
pellets were collected for apoptosis analysis using Annexin V–APC 
and PI per the manufacturer’s instructions (eBioscience). 
 CD8 + T-Cell Depletion and Adoptive Transfer 
 For CD8 + T-cell depletion, mice were injected with 100 µg anti-
CD8 or immunoglobulin G (IgG) control antibodies (Bio-X-Cell) 
once a day, intraperitoneally, for 3 days before tumor injection. A 
total of 250,000 tumor cells were injected into the tail vein on the 
fourth day (day 0). Antibodies were reinjected on day 2 and 7. On 
day 10, mice were euthanized and metastatic burden quantifi ed as 
described earlier. For adoptive transfer experiments, splenocytes from 
tumor-bearing WT and  Ron TK −/− mice were stained with CD8α-FITC 
antibodies and FACS sorted. A total of 500,000 donor CD8 + T cells 
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were injected into the lateral tail veins of recipient  Ron TK +/+ ; Prkdc scid 
mice. Twenty-four hours later, the mice were injected with 250,000 
DiI-labeled tumor cells that were isolated from the same mice as the 
donor T cells. 
 Circulating Tumor Cells 
 Blood was harvested by cardiac puncture on freshly euthanized 
WT and Ron TK −/− mice with tumors. Whole blood RNA was isolated 
using manufacturer’s instructions (Qiagen RNeasy kit). Reverse tran-
scription followed by 35 cycles of PCR for  PyMT RNA was conducted 
using the following primers: 5′-CTCCAACAGATACACCCGCACAT
ACT-3′ (forward) and 5′-GCTGGTCTTGGTCGCTTTCTGGATAC-3′ 
( 50 ). Thirty-fi ve cycles of PCR for glyceraldehyde-3-phosphate dehy-
drogenase on the same samples was conducted using the following 
primers: 5′-ATGTTCCAGTATGACTCCACT-3′ and 5′-CCACAAT
GCCAAAGTTGTCAT-3′  (51 ) and served as a control for normaliza-
tion. Ethidium bromide–stained gels were quantifi ed according to 
pixel density analysis using ImageJ software. 
 Drug Treatment 
 For “prophylactic” treatment, mice were administered 50 mg/kg 
BMS-777607/ASLAN002 (or 70% PEG-400 vehicle) orally once a day 
for 3 days before intravenous injection of 250,000 tumor cells (day 
0 of the experiment). Treatment continued for 10 more days. On 
day 11, mice were euthanized and metastasis quantifi ed as described 
earlier. For “adjuvant” treatment, 250,000 tumor cells were injected 
intravenously (day 0 of the experiment). Beginning on day 14, mice 
were treated with 50 mg/kg BMS-777607/ASLAN002 or vehicle 
orally once a day for 8 days. On day 22, mice were euthanized and 
lungs were fi xed and paraffi n-embedded. The extent of metastasis 
was quantifi ed using ImageJ and calculated as the average tumor 
area versus total lung area on each hematoxylin and eosin–stained 
section.  In vitro activity of BMS-777607/ASLAN002 against murine 
Ron was measured by growing mouse tumor cells (MMTV-PyMT) 
until 80% confl uent, incubating overnight in medium with 0.5% 
serum, and then stimulating the cells with 1 ng/mL recombinant 
human MSP and 0.5, 2.0, or 5.0 µmol/L BMS-777607/ASLAN002. 
Cells were harvested 60 minutes later and analyzed by Western blot 
analysis with phospho-Ron and total-Ron antibodies (1:400; Santa 
Cruz Biotechnology). 
 To determine whether the BMS-777607/ASLAN002 mechanism 
of action was dependent on CD8 + T cells, mice were injected with 
100 µg anti-CD8 or IgG control antibody (Bio-X-Cell), intraperi-
toneally, 7 days before tumor injection and every 5 days until 
euthanasia. Tumor cell injection and drug treatment were identi-
cal to the “prophylactic” treatment protocol. Epithelial cells from 
the lungs were collected following Percol (Sigma) separation and 
analyzed with a FACSCanto II cytometer to calculate percentage of 
DiI-labeled tumor cells. 
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Figure S1. Proliferation and apoptosis of tumor cells was not significantly 
changed in WT versus Ron TK-/- hosts. A. Representative images showing 
immunohistochemical analysis of phospho-histone H3 protein in tumors growing 
in WT or Ron TK-/- hosts, with quantification on the right. B. Representative 
images showing immunofluorescence analysis of TUNEL staining in tumors 
growing in WT or Ron TK-/- hosts, with quantification on the right. C. 
Representative images of PyMT-MSP, 96 hours following i.v injection, showing DiI 
labeled tumor cells (top) in the lungs of WT or Ron TK-/- hosts and subsequent 
Image J image modification for analysis (bottom). D. Representative flow 
cytometric analysis E. Representative images of PyMT-MSP 10 days following i.v 
injection, showing DiI labeled tumor cells (top) in the lungs of WT or Ron TK-/- 
hosts and subsequent Image J modification for analysis (bottom). Data are 
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Figure S2. Loss of host Ron signaling attenuates growth of seeded micro-
metastasis to overt metastasis in a tumor derived MSP-independent 
manner. 
A. Representative flow cytometric analysis (left) and quantification (right) of DiI 
labeled tumor cells in lung 96 hours following intravenous PyMT-MIG tumor cell 
injection into WT or Ron TK-/- hosts (n=7 and 5 respectively)*. B. Representative 
flow cytometric analysis (left) and quantification (right) of DiI labeled tumor cells 
in lung 10 day following intravenous LAP control lung cancer line injection into WT 
or Ron TK-/- hosts (n=5)**. C. Representative flow cytometric analysis of CD11b+ 
macrophages expressing IL-12 isolated from lungs of WT and Ron TK-/- hosts 72 
hours after i.v PyMT-MSP injection. D. Representative flow cytometric analysis of 
CD11b+ macrophages expressing TNF! isolated from lungs of WT and Ron TK-/- 
hosts 72 hours after i.v PyMT-MSP injection. Data are depicted as mean +/- 




















































































































































































































Figure S3.  Most splenic immune cells are present in similar proportions in 
tumor-bearing mice WT and Ron TK-/- hosts. A-F. Flow cytometric analysis of 
macrophages (A), granulocytes (B), myeloid-derived suppressor cells (C), 
dendritic cells (D), CD4+ T cells (E), and regulatory T cells (F). Data are 





























































































































































































































































































































































































Figure S4. Immunodepletion of CD8+ T cells following injection of anti-CD8 
antibody. Flow cytometric analysis of CD8+ T cells in spleens (A), lung (B) and 
peripheral blood (C) of anti-CD8 antibody or control (IgG) antibody injected mice. 
D. Representative images of lung colonization in Ron TK-/- hosts that have been 
treated with control antibody (left) and anti-CD8 antibody (right), with the image J 
quantification on the bottom. E. Representative images of lung colonization in 
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Figure S5. Treatment with a Ron inhibitor, BMS-777607, reduces metastatic 
outgrowth.  A.  Immunoblots (upper) and densitometric analysis (lower) using 
the indicated antibodies on MMTV-PyMT tumor cells (as a source of murine Ron) 
treated with increasing concentrations of BMS-777607 for 60 minutes. Data were 
calculated as ratio of phosphor-Ron to total Ron. B. Representative images of 
metastatic burden in WT hosts that have been treated with vehicle or BMS-
777607. C. Representative flow cytometric analysis of CD11b+ macrophages 
expressing TNF! , isolated from the lungs of tumor bearing WT and Ron TK-/- 
hosts treated with vehicle only versus BMS-777607 96 hours after i.v PyMT-MSP 
injection. D. Representative flow cytometric analysis of labeled tumor cells 96 
hours after intravenous tumor cell injection in animals treated with vehicle or 
BMS-777607 following depletion with an anti-CD8 antibody or IgG control. (n=3-4 
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Supplementary Table 1. Summary of the effect of host Ron on PyMT-MIG 


























Host animal Spontaneous metastasis frequency 
FVB wild type (n=12) 6/12 (50%) 







DISCUSSION AND FUTURE DIRECTIONS 
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My dissertation demonstrates that host MSP/Ron signaling potentiates metastasis 
by suppressing the immune system. In this chapter, I will discuss the unpublished data that 
we have been working on to understand the mechanisms of MSP/Ron-mediated 
immunosuppression. Additionally, I will discuss the future directions and potential 
clinical applications of my dissertation. 
 
Unpublished data on mechanism of MSP/Ron mediated metastasis 
My dissertation has revealed that the MSP/Ron pathway is a key mediator of 
conversion of micrometastases to bona fide metastatic lesions in lungs, through its role in 
suppressing antitumor inflammation (1). Loss of Ron function allows an effective 
antitumor CD8+ T cell response, which is necessary and sufficient to inhibit outgrowth of 
seeded metastatic tumor colonies (1). However, CD8+ T cells do not express Ron; we 
have yet to identify the cell type that responds to MSP, and the subsequent molecular 
mechanisms that suppress CD8+ T cells. Based on previous studies on MSP/Ron signaling 
in the noncancer setting (2), we initially hypothesized that Ron signaling in macrophages 
(M"s)  mediates immunosuppression and ensuing metastasis.  
Mature M"s are the only immune cell reported to express Ron, other than 
hematopoietic stem cells (3). We hypothesized that M"s infiltration would be increased in 
tumors growing in wild-type (WT) hosts, since MSP can function as a M"s 
chemoattractant (4,5). However, immunohistochemical analysis for F4/80+ M"s in 
tumors derived from WT and Ron tyrosine kinase knockout (Ron TK-/-) hosts revealed no 
significant difference in infiltration of M"s into the primary tumors (Appendix). Although 
there was no quantitative difference in M"s infiltration, this did not preclude a qualitative  
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difference between the infiltrating M"s. These data also did not rule out that another cell 
type might contribute. 
To ensure that cells of the hematopoietic lineage mediated the host-dependent 
metastatic difference, we transplanted bone marrow from WT hosts into irradiated Ron 
TK-/- hosts, and vice versa, followed by orthotopic transplantation of PyMT-MSP tumor 
cells. Bone marrow transfer from WT to Ron TK-/- mice was sufficient to restore 
metastasis (Appendix Table A1), demonstrating that the hematopoietic cell compartment 
contains the cell type that mediates immunosuppression. However, transplant of Ron TK-
/- bone marrow into WT hosts was unable to prevent metastasis. Since resident M"s are 
not efficiently depleted with irradiation (6), we hypothesized that the WT M"s may have 
been insufficiently undepleted and still able to promote metastasis. We therefore 
attempted to deplete WT resident M"s using a transgenic mouse with an inducible M"s 
depletion system. Briefly, in this model, the promoter for CD11b, a cell surface molecule 
expressed on myeloid cells such as M"s, drives the human diphtheria toxin receptor 
(DTR), which is 103 to 105 times more sensitive to diphtheria toxin (DT) than the mouse 
DTR (7). The cells expressing the fusion CD11b-DTR (mostly M"s) die when exposed to 
DT. Because the metastatic studies required long term M"s depletion, and because the 
CD1b promoter construct was slightly leaky, causing liver and lung toxicity (7), we had 
first expand CD11b-DTR BM into irradiated hosts to ensure WT hematopoietic-specific 
expression. We then depleted the M"s using DT injection once a day for 10 days. 
Subsequently, we intravenously injected PyMT-MSP into the M"s depleted mice, and 
assayed for metastatic colonization. Depletion of M"s in this setting did not significantly 
impact metastatic colonization (Appendix). However, DTR-mediated M"s depletion may 
be incomplete (8). 
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As a second approach to determine the role of M"s in MSP-mediated metastasis, 
we utilized clodronate-liposome mediated M"s depletion. Liposomes are artificially 
prepared lipid vesicles that encapsulate clodronate, a hydrophilic toxin (9). After injection 
into the mouse, liposomes are ingested by M"s, followed by intracellular release and 
accumulation of clodronate, causing apoptosis of the M"s (9). 
 Liposomal-mediated depletion of M"s also did not significantly impact metastatic 
colonization  (Appendix).  Despite the caveats of the M"s depletion experiments, mainly 
that depletion was never complete, we obtained no evidence to support a role for M"s as 
the Ron-dependent signal to suppress CD8+ T cells. 
These results highlight our difficulty in discovering mechanisms and pathways of 
MSP/Ron-mediated immunosuppression in vivo using our current mouse and tumor 
models.  For example, both DT-and liposome-mediated M"s depletion can cause cell 
death of a wide range of mononuclear phagocytes, including neutrophils, monocytes, 
eosinophils, M"s and dendritic cells, due to some expression of CD-11b in non-M"s cells 
or broad phagocytosis, respectively (10). Such effects could themselves be inflammatory 
(10), confounding interpretation of our results. Moreover, the diversity and plasticity of 
myeloid cells (12), coupled with the redundancies of tumor microenvironmental signaling 
(13), make it very difficult to dissect the molecular mechanisms of immunosuppression. 
More versatile and precise mouse models and tools will be required to dissect the cellular 
and molecular mechanisms by which Ron-expressing immune cells suppress the CD8+ T 
cell response. 
A critical tool to dissect cell-specific Ron functions in vivo is a conditional Ron 
knockout and reporter mouse. In this system, the loxP recombinase recognition sites will 
flank the exons encoding the tyrosine kinase domain of Ron (14).  Cre recombination will 
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result in deletion of the Ron tyrosine kinase domain, and replace it with a fluorescent 
reporter. The resulting allele will express a functionally deficient Ron and a reporter. This 
reporter will mark Ron-expressing cells for fluorescent activated cell sorting (FACS) 
analysis and subsequent molecular profiling and expression analysis. Development of a 
Ron “floxed” reporter mouse will facilitate discovery of functions of Ron in different cell 
types using different Cre drivers (10). 
In this regard, the role of Ron in myeloid cells can be interrogated by using a 
number of different Cre drivers. The intrinsic plasticity of myeloid cells, and the similarity 
between M"s, dendritic cells, and granulocytes (15) make it difficult to generate a cell 
specific Cre driver (10). However, even with this caveat, such models can be used to 
interrogate the function of myeloid cells versus lymphoid or non-hematopoietic 
components. The LysM-Cre model is driven by lysozyme 2, an antimicrobial and cationic 
protein present in M"s and granulocytes (16). Although widely used, this model does not 
distinguish between myeloid cell types, but does exclude CD11c-positive dendritic cells 
(17). Additionally, lysozyme 2 is also expressed in nonhematopoietic cells, including 
myocardial precursor cells (18). It was recently published that Ron deletion using LysM-
Cre impacts primary prostate tumor growth, suggesting that Ron-specific functions in 
myeloid cells during metastasis could be analyzed using that Cre driver (19). A second 
potential driver is the mouse-colony stimulating factor receptor (m-CSF1R, also known as 
c-fms) Cre mouse (20). This promoter is present on dendritic cells, M"s and granulocytes 
(21,22). Importantly, CSF1R mutations cause a selective loss of tissue M"s and 
monocytes (23), suggesting that this Cre driver may be best suited to test hypotheses 
concerning the role of MSP/Ron signaling in tumor-associated M"s. A third possibility 
involves use of CD11c-Cre, a component of the complement receptor (24), which is used 
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to drive Cre in antigen-presenting dendritic cells, and may therefore enable us to 
understand the role of Ron in antigen-presentation (25).  
In addition to a Ron conditional knockout mouse model, a second mouse model 
for temporal analysis of Ron-specific functions in vivo will be a doxycycline inducible re-
expression system. Our lab has developed a tetracycline response element- Ron (TRE-
Ron) transgenic mouse and crossed it onto the Ron TK-/- background. An important next 
step is to cross these mice with a mCSF1R-reverse tetracycline-controlled transactivator 
(mCSF1R-rtTA) (26) mouse to generate a TRE-Ron;mCSF1R-rtTA mouse. In this model, 
treatment of mice with doxycycline will result in rescued expression of Ron in Ron TK-/- 
host CSF1R expressing cells, which include M"s, granulocytes and dendritic cells.  
Another key tool will be a well-defined tumor immunology model. Such a model 
will entail expression of an antigenic protein in tumors that is coupled with an engineered 
matching transgenic T cell receptor (TCR).  One of the most widely used models is the 
OT-1 transgenic model (27).  In this model, CD8+ T cells express a transgenic TCR that 
specifically recognizes the SIINFEKL peptide of ovalbumin (ova) (27). OT-1 CD8+ T 
cells are activated when presented with this peptide (27), making it a powerful tool for 
analyzing immune responses of CD8+ T cells. For tumor studies, PyMT tumor cells would 
need to be moved to a C57/BL6 genetic background and engineered to express the ova 
peptide. Subsequent transplantation into WT or Ron TK-/- hosts that are also transgenic 
for the OT-1 TCR would result in a defined activation of CD8+ T cells in response to the 
tumors. This model will enable us to address basic questions about T cell activation 
dynamics, cytokine production, clonal expansion and other aspects of the anti-tumor 
response of WT and Ron TK-/- hosts. 
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Concurrently with these complicated mouse models, we need to develop a way to 
identify and isolate Ron-expressing hematopoietic cells. It has so far been reported that 
only terminally differentiated resident tissue M"s express Ron (2). Thus, results from 
experiments to detect Ron-expressing cells following FACS sorting with general cell 
surface markers (e.g., CD11b) may be uninterpretable due to the lack of Ron in the 
majority of these cells. Therefore, another important tool will be identifying or developing 
a Ron-specific FACS antibody that binds to the extracellular domain of Ron. This type of 
antibody will minimize the permeabilization and fixation processes, allowing for isolation 
of cells for analysis. Although we have tested multiple Ron antibodies, we have found 
none so far that are suitable for FACS. 
Following generation of these tools, we should be able to answer critical “next-
step” questions that will lead us to discover novel pathways and mechanisms of Ron 
function. 
1. Which immune cells express Ron? A comprehensive analysis of Ron 
expression, using both FACS as well as Ron-specific reporters, will allow us to 
design appropriate assays for Ron function in vivo.  
2. Which molecular signaling pathways are changing in Ron-expressing immune 
cells during metastasis? Given our limited understanding of Ron in the immune 
system, an unbiased approach will be most appropriate. PyMT-MSP tumor cells 
could be injected into Ron conditional knockouts and control hosts. Subsequently, 
Ron-expressing immune cells from tumor bearing mice will be FACS sorted at 
different time points, and from different anatomical locations (i.e., lymph nodes, 
lungs, and primary tumor). These cells will be analyzed by RNA sequencing to 
identify pathways that may contribute to CD8+ T cell activation or suppression.  
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3. Is the TH1 immune response that occurs in Ron TK-/- hosts constitutive, or does 
it require sustained stimulation by myeloid cells? This question can be addressed 
by re-expressing Ron at different time points during the tumorigenic process using 
the tet-regulated system. These data could have implications for how patients are 
selected and treated for clinical trials for Ron inhibitors.  
4. How broadly applicable is Ron-mediated immunosuppression? Does loss of 
Ron contribute to chronic inflammatory conditions? Crohn’s disease and ulcerative 
colitis are chronic inflammatory bowel diseases (IBD) that affect the digestive 
tract (28). The most common symptoms of IBD are abdominal pain, weight loss, 
fever and diarrhea. IBD is a complex genetic disease where environmental factors 
(e.g., cigarette smoking or diet) and infectious microbes interact with genetic 
susceptibility, resulting in a mysregulated immune system that can result in 
mucosal inflammation (28). Genome wide association studies have shown that 
single nucleotide polymorphisms in both Ron and MSP are associated with IBD 
(29,30). Although the exact nature of MSP/Ron signaling in IBD is unclear, it is 
plausible that MSP/Ron immune function may play a role in IBD pathogenesis. 
Despite the lack of tools to make a definitive conclusion, we can speculate on how 
MSP/Ron signaling suppresses CD8+ T cells.  Based on our current understanding of the 
MSP/Ron signaling pathway, MSP/Ron inhibition activates several cytokines that are 
known to boost the activation and priming of CD8+ T cells. These cytokine-signaling 
pathways may also be interdependent, feeding back on each other. In the following 





Potential mechanisms of MSP/Ron mediated immunosuppression 
Firstly, MSP/Ron signaling may enhance the antigen presentation process (Figure 
5.1.). One intriguing possibility in this regard is the intersection of Ron signaling with the 
Signal transducer and activator of transcription (STAT) pathway (31,32). Stat proteins 
play key roles in tumor immunity, with Stat1 increasing antitumor immunity and Stat3 
suppressing antitumor immunity (33). Importantly, Ron deletion has been demonstrated to 
increase Stat1 activation and concomitantly inhibit Stat3 activation (19). Stat3 signaling in 
APCs is a critical pathway that influences the functional outcome of antigen-specific T 
cells (34,35). Stat3-ablated M"s inhibit antigen-specific T cell anergy, making T cells 
more responsive (36). Although this mechanism is unclear, it is hypothesized that, in the 
absence of a functional Stat3 protein, APCs exhibit increased CD8+ T cell activating 
capacity. Stat3-ablated M"s are better than wild-type M"s at acquiring and processing 
antigen for effective cross-presentation to CD8+ T cells (37).  
Since Ron TK-/- myeloid cells have decreased levels of Stat3 (2,19) they may 
more effectively cross-present antigen when compared to WT M"s. It would be 
interesting to determine if Ron TK-/- myeloid cells maintain this enhanced ability to 
capture and cross-present antigens in the tumor suppressive microenvironment. This 
hypothesis can be tested utilizing in vitro antigen presenting assays. Ron-expressing  
myeloid cells from WT mice or Ron TK-/- mice will be sorted by FACS. The sorted 
myeloid cells will be pulsed with ova peptide and cocultured in vitro with ova-specific 
CD8+ T cells from an OT-1 mouse. The CD8+ T cell response will be analyzed by FACS 
for TNF-#, IFN-%, Grz-B, as well as CD8+ T cell proliferation. This assay will determine 
if Ron TK-/- myeloid cells robustly activate CD8+ T cells when compared to WT myeloid 





Figure 5.1. MSP/Ron signaling may enhance the antigen presentation process. 
MSP/Ron signaling may result in suppression of CD8+ T cell response by preventing stat1 
activation and activating Stat3 signaling. Stat1 has been shown to play a role in activating 
CD8+ T cells by the process of cross-presentation, while Stat3 downregulates MHC 
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lymphocytic choriomeningitis virus (LCMV) (39). Ron-expressing myeloid cells from 
WT or Ron TK-/- hosts will be sorted, pulsed with an LCMV peptide, and adoptively 
transferred into naïve mice. These naïve mice will then be challenged with LCMV. The 
mice that have been injected with the more effective antigen presenting APCs will mount 
a stronger immune response as assessed by the same parameters as described for the in 
vitro assays. To determine if Stat signaling proteins are downstream of Ron in antigen-
presentation, the presence or absence of Stat proteins will be analyzed by fluorescence 
activated cell sorting (FACS). More detailed genetic studies, where Ron TK-/- mice and 
WT mice are crossed with Stat 1 (38) and Stat 3 knockout mice (37), will need to be 
undertaken to dissect the interaction of Ron and Stat proteins.  
In addition to cross-presentation, Stat3 deficient M"s have enhanced expression of 
MHC class II, a molecule involved in CD4+ T cell activation (34). Loss of Stat3 results in 
decreased expression of arginase (40,41), whose expression in APCs down-regulates 
MHC class II molecules (42). L-arginine is required for MHC class II expression on APCs 
and under L-arginine–deficient conditions, as is the case when Stat3 is activated, APCs 
have decreased MHC II antigen-presenting ability to CD4+ T cells (42). Like Stat3-
activated M"s, MSP activity on M"s increases arginase expression (43,44), and 
decreases MHC class II molecule expression (31). Thus, Ron-expressing immune cells 
may be skewed toward less decreased CD4+ T cell activation, resulting in less effective 
CD8+ T cell activation. Accordingly, Ron ablation may also cause APCs to present more 
effectively to CD4+ T cells, thereby leading to efficient CD8+ T cell activation. Although 
the proportion of CD4+ T cells in the spleen of tumor-bearing WT and Ron TK-/- hosts 
were not statistically significant, we observed a trend of increased CD4+ T cells in Ron 
TK-/- hosts (1). This hypothesis can initially be tested in the experimental metastasis 
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setting, depleting CD4+ T cells in Ron TK-/- hosts and testing the expansion of CD8+ T 
cells and resulting effect on metastatic colonization.  
Stat3 inhibitors that directly inhibit Stat3 phosphorylation (45), or, 
peptidomimetics that inhibit dimerization (46), are currently in preclinical development 
(33). However, there are few Stat3 inhibitors nearing clinical trials, mainly due to the 
difficulty of identifying a suitable inhibitor that targets the large surface area of the 
protein-protein interactions (47). It will be interesting to determine if inhibition of Ron by 
BMS-777607 results in inhibition of the Stat3 pathway and/or promotes Stat1 signaling, 
thus skewing the immune system toward a TH1 response.  
Secondly, MSP/Ron signaling may skew the production of cytokines (Figure 5.2). 
Antigen presentation is not the only mechanism that activates CD8+ T cells. The potency 
of an immune response is dictated by the particular APC as well as the context 
(inflammatory versus noninflammatory) in which the APC acquires the antigens for 
processing and presentation (48,49). CD8+ T cells that are exposed to strong inflammatory 
signals, such as interleukin-12 and interferon-% (IFN%), undergo strong proliferation and 
activation (50). Conversely, in the absence of a strong inflammatory signal, CD8+ T cells 
undergo tolerance (51). Thus, APCs isolated from tumors (which are naturally selected for 
lack of strong inflammatory signals) are inefficient at priming adaptive immune 
responses, thereby inducing T cell tolerance (52,53). Indeed, tumor-associated M"s 
display activated Stat3 (54–56), which upregulates immunosuppressive factors, including 
interleukin-10 (57) and vascular endothelial growth factor (VEGF) (58), and do not 











Figure 5.2. MSP/Ron signaling may skew the production of cytokines. MSP/Ron 
signaling in the tumor microenvironment may result in a skewing of cytokine production, 
thereby impacting CD8+ T cell activation and response. Notably, MSP has been reported 
to upregulate IL-10, an immunosuppressive cytokine, and downregulate several cytokines, 




IL-10 IL-12 IL-15 IL-18 
CD8
+ 
T cell response 
  
101 
Conversely, Stat3-deficient M"s and neutrophils have increased levels of pro-
inflammatory mediators, including IL-12, IFN%, and nitric oxide, thereby leading to more 
potent antitumor responses (54). 
WT M"s that are stimulated with MSP have a consistently immunosuppressive 
cytokine profile, expressing higher levels of IL-10, and decreased levels of IL-12 
(Appendix). Conversely, loss of Ron results in increased levels of proinflammatory 
cytokines including IL-12 and TNF-# (1,2,31,32,60). Thus, an alternative hypothesis is 
that loss of Ron simply causes a proinflammatory microenvironment that increases the 
potency of the resulting CD8+ T cell response, rather than directly influencing the antigen 
presenting capacity of the APCs. This hypothesis can also be addressed in a viral infection 
model (61). Under this system, ova-specific CD8+ T cells derived from the OT-1 
transgenic model are cultured for 3 days in vitro, together with WT or Ron TK-/- APCs 
pulsed with ova. The CD8+ T cells are then labeled with fluorescent dye, and transferred 
into naïve mice. In the presence of a robust inflammatory signal during the in 
vitro stimulation, the CD8+ T cells will continue to expand for several days following 
transfer, and then undergo a contraction phase. The surviving cells will have a “memory” 
phenotype and will rapidly re-expand and protect against challenge with Listeria that is 
engineered to express ovalbumin peptide. In the absence of IL-12 or IFN#/! during the 
initial response to antigen, T cells will proliferate at low levels. Thus, if Ron TK-/- APCs 
cause an inflammatory microenvironmental cytokine milieu, CD8+ T cells will have more 
robust proliferation. To differentiate the ensuing proliferation from antigen-presentation, 
adding conditioned media from Ron TK-/- cocultures to WT cultures, or adding 
exogenous IL-12 to the WT cultures should rescue the proliferation phenotype. Inhibition 
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of IL-12 in the Ron TK-/- cocultures using anti-IL12 antibodies is hypothesized to 
abrogate the robust proliferation.  
In addition to IL-12, the expression of IL-15 and IL-18 are also inhibited by MSP 
(32).  Interestingly, IL-15 plays a significant role in T-cell activation and effector 
functions (62), including T cell proliferation, TNF-# production (63) and cytotoxicity 
(64,65). Blocking IL-15 or IL-15R on dendritic cells in the context of a viral infection 
resulted in increased CD8+ T-cell apoptosis in the lung and inefficient viral clearance (66). 
CD8+ T-cell survival was dependent on IL-15 activity. Intriguingly, engineering tumor-
specific T cells to express IL-15 enhanced T-cell survival, and resulting in improved 
antitumor effects (67).  
In addition to IL-15, MSP suppresses IL-18 production (32). IL-18 is produced by 
many cell types including M"s (68), dendritic cells (69), epithelial cells (70), and 
osteoblasts (71). The IL-18 receptor is upregulated on T cells and B cells in response to 
IL-12 (72). IL-18 is a chemoattractant for CD8+ T cells (73), and contributes to the 
expansion and effector responses of antigen-specific CD8+ T cell populations (74), and 
enhances the killing activity of NK cells (75,76). Treating tumor-bearing mice with IL-18 
results in tumor growth inhibition (77). Additionally, IL-18 as an adjuvant enhances the 
antitumor efficacy of a DNA-based vaccine (78).  
Thirdly, MSP/Ron signaling may alter the metastatic niche (Figure 5.3). In 
addition to potential roles in priming and activating CD8+ T cells, loss of host MSP/Ron 
may impact CD8+ T cell proliferation and/or apoptosis within the metastatic niche. 
MSP/Ron signaling controls the balance of inducible nitric oxide signaling versus arginase 
1 production(2). MSP/Ron signaling inhibits the expression of inducible nitric oxide 







Figure 5.3. MSP/Ron signaling may alter the metastatic niche. MSP/Ron signaling has 
been shown to regulate the production of factors that remodel the tumor 
microenvironment. Specifically, MSP/Ron signaling upregulates arginase and 
downregulates nitric oxide. This signaling pathway has been shown to play a role in CD8+ 
T cell response. Moreover, MSP/Ron activity results in increased ROS, which have been 
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Ron-ablated M"s have increased levels of NO both in vitro and in vivo, rendering Ron 
TK-/- mice more susceptible to LPS-induced endotoxic shock (43,80). Conversely, 
peritoneal M"s stimulated with MSP upregulate arginase, which competes with iNOS for 
their common substrate L-arginine.  
iNOS catalyzes the synthesis of NO and citrulline from L-Arginine (81) and is a 
hallmark of classically activated M"s (82). By contrast, Arg1 catalyzes the hydrolysis 
of L-Arginine to L-ornithine and urea (83), and is a hallmark of alternatively activated 
M"s (82). In addition to upregulation by Ron, Arg1 expression is induced in myeloid 
cells by several cytokines including TGF-!, GM-CSF, and IL-4 (84–87).  
Increased arginase expression causes depletion of extracellular L-Arginine 
concentration, which causes T cells hyporesponsiveness, such as decreased proliferation 
and cytokine synthesis (88–90). Although the mechanism is unclear, arginine 
downregulates the CD3( T cell receptor (91), which subsequently inhibits interleukin 2 
receptor signaling pathway (involved in CD8+ T cell proliferation) (92).  Thus it is 
plausible that MSP/Ron signaling induced skewing of the arginase balance results in 
increased CD8+ T cell apoptosis, and loss of MSP/Ron signaling relieves this apoptotic 
stress. Ron signaling could also impact CD8+ T cell proliferation and activation by 
controlling the production of reactive oxygen species (ROS). ROS are a class of 
molecules including superoxide anion (O2) and hydrogen peroxide (H2O2), which cause 
CD8+ T cell apoptosis in vitro and in vivo (93,94). For example, in a viral infection model, 
increasing the levels of ROS caused a 10-fold decrease of antigen specific CD8+ T cells 
due to increased T cell apoptosis (95). In the tumor microenvironment or metastatic niche, 
myeloid cells produce high levels of ROS that can inhibit antigen-induced proliferation 
and response of CD8+ T cells. 
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Accordingly, inhibiting ROS in myeloid cells removes the inhibition on CD8+ T cells 
(96). MSP signaling has been reported to induce a dose-dependent superoxide anion 
production in human alveolar and peritoneal M"s as well as in monocyte-derived M"s, 
but not in circulating human monocytes (97). Superoxide itself is very unstable and is 
converted to H2O2 and O2  (96). This is consistent with data suggesting that ROS 
accumulates primarily in form of H2O2, but not superoxide in the tumor 
microenvironment. Thus, we can speculate that WT myeloid cells release ROS, which 
subsequently kill the CD8+ T cells. This hypothesis predicts that inhibiting ROS using 
small molecules in WT hosts may prevent CD8+ T cell apoptosis. Conversely, increasing 
ROS in Ron TK-/- hosts using small molecules would be predicted to result in 
immunosuppression and increased metastasis. 
Finally, MSP/Ron signaling may result in direct upregulation of cytolytic CD8+ T 
cell activity. Loss of MSP/Ron signaling relieves immunosuppression of CD8+ T cell and 
results in production of TNF-# in CD8+ T cells (1). TNF-# regulates multiple aspects of 
the antitumor response (98). For example, TNF-# mediated killing of infected cells by 
CD8+ T occurs after cross-presentation (99). Moreover, there is a feedback loop between 
T cells and APCs, whereby TNF-# produced by CD8+ T cell binds to the TNF-#-receptor 
on APCs (100). This results in upregulation of positive costimulatory signals such as 
CD40 and CD86 costimulatory molecules on APCs, thereby increasing the potency of the 
immune response. Consequently, TNF-#–/– and TNF-# receptor –/– APCs have an impaired 
ability to mature in response to limited or suboptimal inflammatory conditions, such as 
those encountered in the tumor microenvironment (100). Thus, inhibition of Ron signaling 
may initiate an inflammatory signaling loop, strengthening the immune response. 
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Crossing the Ron TK-/- with TNF-# knockout mice will test if this feedback loop is 
necessary for the decreased metastasis and immunosuppression. 
 CD8+ T cells also can kill cells via the production of granzyme B, IFN-%, and 
TNF-# (101). We have assayed for the expression of each of these cytolytic molecules in 
our models, but observed no significant differences in IFN-% or Granzyme B (Appendix 
A5). The population of antigen-specific CD8+ T cells at any given time is low (49). Thus, 
without restimulating these CD8+ T cells with a specific antigen, it is difficult to detect 
these lytic molecules. Thus, development of tumor models with a defined antigen, (e.g., 
OT-1 transgenic mice) will allow us to specifically measure the expression of these 
molecules in response to specific antigens. Genetic models, in which granzyme B, or other 
lytic molecules are ablated, will also enable us to functionally determine the contribution 
of particular CD8+ T cell lytic pathways. 
In summary, published data suggest that MSP/Ron signaling can impinge on CD8+ 
T cell activity in several ways; by impacting antigen presentation, by skewing cytokine 
production in the tumor microenvironment, by altering the metastatic sites or by directly 
upregulating cytolytic molecules in CD8+ T cells.  These various known mechanisms 
downstream of MSP/Ron that I have described were originally defined in infection or 
inflammation models, but may also be relevant to the tumor setting. Moreover, it is 
plausible that many of these pathways are acting in concert during tumor-mediated 
immunosuppression. Additionally, the pleiotropic effect of MSP/Ron signaling suggests 
that there may be broader applications to inhibiting this pathway, including in viral 







Cancer immunotherapy utilizes the anticancer immune response or components of 
the immune system as cancer treatment (102). The history of cancer therapy shows 
waxing and waning of enthusiasm for cancer immunotherapy (102). Although there are 
multiple reasons why immunotherapy been disappointing, a key indicator is that cancer 
progression is, in itself, a sign that the complicated and interconnected immune regulatory 
system has failed. Thus, given the enormous complexity of the system and the numerous 
unresolved regulatory pathways, it has been difficult to understand which signaling nodes 
are critical for this immune failure, and whether they can be manipulated to design 
effective therapies. We consider MSP/Ron signaling to be an immune system “rheostat,” 
tempering the immune response to various insults. Our data suggests that tumors can 
subvert this built-in regulatory pathway to evade the immune system. Thus, inhibiting 
MSP/Ron signaling in the host, if it in fact works to reactivate the immune system, could 
have immense clinical impact.  
Historically, a major roadblock in immunotherapy and metastatic drug 
development is the unsuitability of the Response Evaluation Criteria In Solid Tumors 
(RECIST) parameters to assess efficacy (103). RECIST measures the efficacy of a therapy 
depending on tumor shrinkage, whereby an increase in tumor size and/or the appearance 
of new lesions is considered to be a treatment failure (104). However, these criteria do not 
readily apply to immunotherapy (104). Immunotherapy-induced tumor regressions can 
occur after initial tumor progression, and even after the appearance of new lesions. For 
example, in some patients receiving ipilimumab, an inhibitor of the immune-suppressive 
CTLA-4, metastases grew or new lesions developed before there was a decline in total 
tumor burden (105).  
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Thus, compared to classic chemotherapy, successful immunotherapy may have a 
variable clinical response, with four patterns of response (106). First, some patients show 
immediate response and tumor size decreases. Second, some patients show durable stable 
disease with a possible slow decrease in tumor burden. Third, there are responses after an 
initial tumor burden increase (possibly due to lymphocyte infiltration). Finally, there is a 
response in the appearance of new lesions, with some lesions decreasing and others 
increasing. In addition to the variable clinical response, it is difficult to define the optimal 
treatment schedule for immunotherapies, due to an insufficient correlation between the 
maximal tolerated dose and the maximal effective dose (102). Clinical responses 
following immunotherapy have several implications for bringing Ron inhibitors to the 
clinic, namely clinical trial design and patient selection. 
Appropriate patient selection is crucial for immunotherapeutic success (103). 
Although our data shows that loss of Ron can affect metastasis in an MSP-independent 
manner (1), expression of MSP/Ron/Matriptase and its association with poor prognosis 
(107) suggests that this population may be most suitable for clinical trials with Ron 
inhibitors. Overexpression of MSP, in particular, may indicate that the tumor may be 
evading immune response through host Ron signaling. Selection of patients with 
appropriately staged tumors may also be critical for success in immunotherapeutic settings 
(108). Immunotherapy is ineffective in patients with a large tumor burden, both due to the 
correlation of tumor burden and immune suppression, and the delay in the time taken to 
translate immune responses into a survival benefit (109–113). Thus, Ron inhibitors for 
immunotherapy would ideally be tested in a low volume and/or microscopic adjuvant 
disease setting.  
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Appropriate choice of response criteria will also be critical for successful 
assessment of the efficacy of Ron inhibitors in the clinic. The immune-related response 
criteria (irRC) was adopted to capture the spectrum of clinical patterns of antitumor 
response for immunotherapeutic agents (106). irRC calculates tumor burden as a 
continuous variable. Accordingly, the percent change in tumor burden between 
assessment time points describes the size and growth kinetics of total measurable tumor 
burden over time (106). Using irRC, the appearance of new lesions alone does not 
constitute progressive disease, if it does not add to the tumor burden by at least 25% 
(106). Importantly, early increase in the size of lesions, which may be due to the 
infiltration of lymphocytes, does not mean that the treatment has failed, as a response may 
be obtained at the next time point (106). These features of immunotherapeutic responses 
make it important to use different statistical methods for trial design and analysis of 
survival outcomes (114).  
Appropriate statistical analysis of Ron inhibitor clinical trials will be key to assess 
efficacy. Unlike chemotherapy, for which an early clinical effect is possible, 
immunotherapies demonstrate delayed clinical effects. The current statistical methods 
used to analyze clinical trials are unable to calculate the delay in survival benefits that 
may occur due to immunotherapies (115–117). This may increase the chance of a negative 
early analysis, and of concluding ineffectiveness because of projected results without a 
delayed separation (114). This can be avoided by conducting randomized Phase II clinical 
trials to assess survival curves, thereby allowing better planning of statistical analyses in 
phase III clinical trials.  
Immunotherapies also have a different range of toxicities than cytotoxic drugs 
(118). For example, ipilimumab is associated with the development of immune-related 
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adverse reactions such as colitis, dermatitis, hepatitis and endocrinopathies. Although 
MSP-/- mice and Ron TK-/- mice are viable and developmentally normal, they exhibit 
increased inflammation in response to exogenous challenges (119,120). Thus, a potential 
side effect of Ron inhibition could include the inability to downregulate the inflammatory 
response following a severe infection or injury, suggesting that Ron inhibitors may have 
to be temporarily withdrawn during serious injury or infection. 
Tracking immune responses is critical during immunotherapies, and should be 
done with immune-specific biomarker assays (114). There bioassays include enzyme-
linked immunosorbent spot assays and FACS for intracellular cytokines (114). Our results 
show that loss of Ron increases expression of TNF-# in CD8+ T cells (1). Thus, one 
potential biomarker for drug response would be a cytokine panel for TNF-# and 
potentially other T cell activation markers. Additionally, profiling our tumors for cytokine 
differences uncovered that tumors from WT hosts express significantly more interleukin 
1-! (IL-1!) when compared to Ron TK-/- hosts (Appendix). Additionally, culturing M"s 
in the presence of MSP for 72 hours results in increased levels of IL-1!  (Appendix). This 
suggests that downregulation of IL-1! in tumors or M"s may be a biomarker for Ron 
inhibition. IL-1! is an “alarm cytokine” that is secreted by M"s, initiates inflammation 
and may play a role in promoting immune tolerance (121). Secretion of IL-1!, by both 
tumor cells and stromal cells, has been reported to induce T cell anergy (122), and 
correlates with the accumulation of myeloid-derived suppressor cells in the peripheral 
blood, spleen, and tumor (122). However, antibody mediated depletion of IL-1! 
(Appendix) in our model did significantly affect metastatic outgrowth. Thus, although IL-
1! may not be a mechanistic driver of Ron-dependent metastasis, it may potentially serve 
as a biomarker for Ron activity.  
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Synergy of Ron inhibitors with chemotherapeutic agents and vaccines would 
theoretically increase the potency of the immune response. Vaccines effectively prevent 
many pathogen infections (123). This success, as well as the recent approval of sipuleucel-
T (124), an antigen-presenting cell vaccine for prostate cancer, has generated immense 
interest in using vaccines to treat or prevent cancer patients (125). However, the 
etiological agents for most human cancers remains unknown (126); therefore, vaccines 
may be more useful in the short term as therapeutics rather than preventatives. 
Therapeutic vaccines attempt to stimulate the patient’s immune system to respond to an 
existing cancer (125). Unfortunately, the endogenous T cell repertoire lacks high-avidity 
clones due to thymic negative selection (127). Moreover, those T cells that have escaped 
thymic negative selection are subjected to highly regulated peripheral tolerance 
mechanisms (128). These mechanisms, combined with the negative influence of the tumor 
microenvironment and other immunosuppressive factors, have contributed to the limited 
success of vaccines (125,129,130). However, preclinical studies show that vaccine 
combination with either immune stimulants or inhibitors of immune suppression, greatly 
enhances antitumor responses (131,132).  Our results demonstrate that because Ron 
inhibition breaks immunosuppression, combination therapy with a Ron inhibitor and 
antitumor vaccine may be effective. However, preclinical proof-of-concept experiments 
are needed to validate this. 
How would one design and validate a vaccine/Ron inhibitor combination? 
Vaccination is often grounded on identifying an antigen that will stimulate T cell activity 
in a tumor-specific manner (133). Preclinically, a proof of concept experiment would 
involve pulsing APCs with the ovalbumin peptide, for example, followed by adoptive 
transfer into a PyMT-ovalbumin tumor-bearing Ron TK-/- hosts or WT hosts treated with 
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Ron inhibitors. If we determine that Ron inhibitors significantly impact metastasis and 
tumor growth by synergizing with vaccines, the next step would be to combine Ron 
inhibitors with vaccines in current clinical trials (125). These vaccines are based on 
peptides from known tumor-associated antigens, and are administered with an adjuvant 
and/or other immune modulators. For example, current vaccines are targeted to 
overexpressed HER2/neu (134), and oncofetal antigens such as carcinoembryonic antigen 
(CEA) (135), and mucins (136). Although these approaches may prove clinically 
beneficial, there are currently no approved vaccines that are in clinical use for breast 
cancer.  
Chemotherapy-induced immune activation (102,137) opens up the exciting 
possibility that Ron inhibitors could potentially synergize with chemotherapy to impact 
tumor growth and metastasis. It is currently unknown which chemotherapy combinations 
have the most impact when combined with Ron inhibitors. Thus an important experiment 
will be to determine which combinations are most effective.  
Although some chemotherapy treatments may have immunosuppressive effects, 
seen with high-dose cyclophosphamide (138) and folate antagonists (139), response to 
chemotherapy and targeted therapies is, in part, regulated by the immune system 
(137,140–142).  Chemotherapies used in breast cancer can induce various tumor cell death 
pathways, leading to the release of tumor-associated antigens that can activate immune 
cells. Oxaliplatin and anthracyclines such as doxorubicin induce “immunogenic tumor cell 
death,” which enhances cross-presentation of tumor-associated antigens by DCs, and 
subsequent activation of T cells (143,144). Doxorubicin has been shown to increase 
antigen-specific CD8+ T cell proliferation in tumor-draining lymph nodes, and promotes T 
cell infiltration into tumors (145). Taxane microtubule inhibitors are a class of cytotoxic 
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agents that are considered to be the standard of care for treatment of metastatic disease 
(146). Paclitaxel, a taxane, inhibits regulatory T cells, thereby rendering tumor cells 
susceptible to CD8+ T cell-mediated lysis (147,148). Docetaxel, used for the treatment of 
anthracycline-resistant breast cancer, has been reported to decrease splenic MDSC levels 
in tumor-bearing mice (149). Gemcitabine, a nucleoside analog (150), increases the 
expression of class I human leukocyte antigen (HLA) on tumor cells, (151) and augments 
the cross-presentation of tumor associated antigens to CD8+ T cells (140). Platinum-based 
chemotherapies (including cisplatin and carboplatin) also increase HLA expression, and 
can relieve immunosuppression by limiting expression of programmed death ligand 2, a T 
cell inhibitor (152).  
A significant hurdle to developing and testing Ron inhibitors and combinations as 
immunotherapies is the absence of human immune-competent preclinical mouse models 
(153). Current mouse models may not predict the clinical response to immunotherapies 
(154). Although experiments in mice with tumors expressing xenogeneic proteins that are 
coupled with transgenic T cells are used to address questions about the antitumor immune 
response (155–157), they may be inadequate for modeling the human immune response to 
immunotherapy strategies due to the foreign nature of the antigens (158). Thus, a mouse 
model with human tumors and human immune system (159) may provide a better method 
to test Ron inhibitors, alone and in combination. In this model, immunodeficient mice are 
being engrafted with human hematopoietic cells to generate a functional human immune 
system (159). Consequently, these mice would have both a human immune system and 
human cancers. This type model would be ideal to test drugs for Ron and check for 
chemotherapy combinations.  
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In summary, our finding that MSP/Ron signaling enables metastasis by 
suppressing the immune system has revealed many questions about mechanism and 
function.  To answer these questions will require the development of more versatile and 
precise animal models. Moreover, our finding that MSP/Ron signaling may function as an 
immunotherapy in the metastatic setting has important implications for clinical trial design 
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Figure A.1. Levels of macrophage infiltration in PyMT-MSP tumors in WT and Ron 
TK-/- hosts are similar.  Representative immunohistochemistry analysis of macrophage 
infiltration into WT or Ron TK-/- hosts. Paraffin fixed- PyMT-MSP tumors were stained 
with F4/80 (1:100) 1 hour at room temperature. There was not a significant difference in 
the level of infiltration of macrophages. !!!!!!!!!



















Table A.1. The myeloid compartment is responsible for the metastatic effect. 
WT and Ron TK-/- hosts were irradiated with 900 rads, followed by tail vein injection of 
1x106 bone marrow cells from WT or Ron TK-/- hosts. Three months later, 100,000 
PyMT-MSP expressing cells were injected orthotopically and metastasis to the lungs was 
analyzed. Our results show that WT bone marrow is sufficient to restore the metastatic 
effect in Ron TK-/- hosts. 
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Figure A.2. Diphtheria-toxin mediated macrophage depletion does not significantly 
decrease metastatic colonization. WT hosts were irradiated with 900 rads. Subsequently, 
1x106 bone marrow cells from Diphtheria-toxin receptor mice were injected into the tail 
vein. One month later, the mice were injected with diphtheria toxin. 250,000 PyMT MSP 
tumor cells were injected into the tail vein. Ten days later, the animal was sacrificed, and 












































Figure A.3. Liposome-clodronate mediated macrophage depletion does not 
significantly decrease metastatic colonization. WT and Ron TK-/- hosts were treated 
with lipsome-clodronome or control clodrosome. Subsequently, 250,000 PyMT MSP 
tumor cells were injected into the tail vein. Ten days later, the animal was sacrificed, and 
lungs sectioned and colonies quantified. Depletion of macrophages with liposome did not 















































































Figure A.4. WT macrophages have an immunosuppressive cytokine profile. WT 
macrophages and Ron TK-/- bone marrow derived macrophages were stimulated MSP 
(100ng/mL) for 72 hours. WT macrophages had an increased IL10/Il-12 ratio, indicative of 












































Figure A.5. CD8+ T cell expression of Granzyme B+ is similar between WT and Ron 
TK-/- hosts. Graph depicting the population of Granzyme B+ expressing CD8+ T cells in 








































Figure A.6. IL-1! protein is significantly decreased in PyMT-MSP tumors from Ron 
TK-/- hosts. PyMT-MSP tumor lysates were isolated using our previously published 
protocol. The tumors were subsequently analyzed using the MSD cytokine profile as per 
manufacturers instructions.  The results show that IL-1! levels are decreased in tumors 




















































Figure A.7. IL-1! mRNA levels in WT macrophages are increased 72 hours after 
MSP stimulation. Bone marrow derived macrophages were differentiated using 
Macrophage Colony Stimulating Factor for 10 days. Subsequently, they were transferred to 
a serum free media, and stimulated with MSP for 72 hours (100ng/mL). RNA was isolated 
using Quiagen RNA isolation protocol, and expression of IL-1! analyzed using RT-PCR. 





































Figure A.8. IL-1! inhibition does not decrease metastatic colonization. WT hosts were 
treated with an anti-IL-1! antibody. Subsequently, 250,000 PyMT-MSP tumor cells were 
intravenously injected, and metastatic colonization analyzed. IL-1! inhibition does not 
prevent outgrowth of metastatic outgrowths. 
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